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SUMMARY
The thesis is divided into two parts. Both deal with the microbial metabolism of  
benzene derivatives but in different aspects.
Part I attempts to elucidate some new mechanisms and stereochemistry involved  
in m ucon ic  acid pathways, which com m only  occur in the microbial degradation o f  
b en zen e  derivatives .  To investigate  the con vers ion  o f  4 -m eth y l into 3-m ethy l-  
muconolactone, three specially labelled muconolactones were tested with cell-free extracts 
o f  R h o d o co ccu s rh odocrou s. The results showed that the conversion o f  4-methyl to 3- 
m eth y lm u co n o la cto n e  proceeds through two steps. Firstly, e n z y m e  cata lyses  the 
formation o f  the new lactone ring by anti addition. Secondly the original lactone ring is 
opened en zym ica lly  by anti elimination. Dilactone was shown to be an intermediate. 
Studies on the inhibitors o f  the methylisomerase have been carried out from chemical  
point o f  v iew . A m ong the substituents studied, the larger substituents did not affect the 
biotransformation o f  pyrocatechols into corresponding muconolactones in P seudom onas  
p u tid a  but affected those in A sperg illu s n iger. It was shown that the optical active 4- 
ethylm uconolactone can cyclise under mild condition giving the dilactone with opposite  
optical rotation, but 3 ,4-d im ethylm uconolactone can not be cyc l ised  under various  
conditions.
In part II, it was hoped to delineate some influences of  fluorine substituents on 
the b iosyn th es is  o f  cyc lop en in  group o f  benzodiazepine  alkaloids. Three f luoro­
phenylalanines were tested with the fungus Penicillium  cyclopium . The qualitative results 
obtained sh ow ed  that these substrates have been incorporated into benzodiazepine  
alkaloids with low yields.
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PART I CHAPTER 1: INTRODUCTION
P A R T
O N E
STUDY OF THE MECHANISMS OF 
MUCONIC ACID PATHWAYS
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PART I CHAPTER 1: INTRODUCTION
CHAPTER
_________ ONE
IN T R O D U C T IO N
Part I o f  the thesis  attempts to e luc idate  so m e  n ew  m ech a n ism s  and 
stereochem istry involved  in m uconic acid pathways, which c o m m o n ly  occur in the 
microbial degradation o f  benzene derivatives. In introducing the work em bodied in this 
part, som e c lo se ly  related research is reviewed in this chapter. A general review of  
m uconic  acid pathways from a historical prospect is firstly outlined. The fo llow ing  
section  sum m aries the en zy m o lo g y  o f  the m uconic acid pathways, where we discuss  
each particular enzym e mainly from bacteria. The isolation, purification and biochemical  
properties o f  m uconolactone 4-methylisomerase are stressed. Then the stereochemistry  
involved in the muconic acid pathways is discussed in Sec. 1.3, in which the conversion  
of 4-methyl- into 3-methyl-muconolactone is o f  particular interest to the present research. 
Finally, the aims o f the present project are presented.
1.1 A GENERAL REVIEW OF MUCONIC ACID PATHWAYS
1.1.1 M icrobial Degradation of Benzene Derivatives
P estic ides,  herbicides, synthetic detergents and waste products o f  chem ical  
industries constitute a formidable addition of foreign chem icals to the two major sites of
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biological dissimilation: the soil and natural water. Some of these are very poisonous 
substances and could be hazardous to life if they accumulated in the environment. The 
ultimate destruction and removal of them from the biosphere is mainly dependent on 
microbial action and therefore is of world-wide importance. Numerous workers have 
described the isolation of micro-organisms from various sources and their capabilities to 
degrade aromatic compound (Refs. 1-7).
The oxidative attack on those chemicals carrying an aromatic ring in both bacteria 
and fungi leads to the formation of either pyrocatechol or its derivatives, which are the 
substrates for oxygenase-catalysed ring cleavage, and are therefore the last intermediates 
possessing an aromatic structure (Scheme 1) (Ref. 5).
CRESOLS BENZENE MANDELATEv \ y
'  “- A *
I ^
PHTHALATE NAPHTHALENE L-TRYPTOPHAN
Scheme 1.
The ring cleavage of the aromatic nuclei proceeds via two different pathways 
according to the mode of ring-fission (Ref. 8). In many microorganisms, aromatic rings 
are metabolized by the so-called Wfa-cleavage' illustrated in Scheme 2. The degradation 
of pyrocatechol (1) in a naphthalene-grown Pseudomonad gives 2-hydroxymuconic 
semialdehyde (2), which can either be enzymically hydrolysed with loss of formate, or 
be enzymically further oxidised and decarboxylated to 2-oxo-pent-4-enoic acid (5) with 
(3) and (4) as intermediates. After hydration of (5), compound (6) is split into 
acetaldehyde and pyruvate, which enters into the tricarboxylic acid cycle (TCC) (Scheme 
2) (Ref.9). Alternatively, a large number of microorganisms can metabolize pyrocatechols
3
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after orf/w-cleavage, i.e. by cleavage between the two hydroxyl groups, to give muconic 
acids as key intermediates, which can be converted into 3-oxoadipates so that they enter 
into the Krebs cycle eventually. This pathway (the muconic acid pathway) (Scheme 3) 
provides a mechanism for the utilization of many different aromatic substrates, and has a 
wide taxonomic distribution, both among bacteria and fungi. In the simplest case, 
pyrocatechol (1) is converted by bacteria or fungi with uptake of oxygen into cis,cis- 
muconic acid (7), which is cyclized enzymically to the muconolactone (8) (Scheme 3). 
This lactone (8) is then converted into 3-oxoadipic acid (10) via the enol-lactone (9). 
The 3-oxoadipic acid (10) is further degraded to the metabolically useful acetic and 
succinic acids, which are constituents of the tricarboxylic acid cycle (TCC) (Ref. 10).
In the following text, we will only cite those which are the most closely related to 
the muconic acid pathway and the present project.
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1.1.2 The Muconic Acid Pathways
The 'classical' muconic acid pathway shown in Scheme 3 was established 
gradually before any attention was given to the characterisation of the relevant enzymes 
and the stereochemistry of the various steps. The formation of the muconic acid (7) as the 
product of bacterial attack on pyrocatechol (1) was first demonstrated by Hayaishi and 
Hashimoto in 1950 (Ref. 11). The definitive characterization of this acid as cis.cis- 
muconic acid (7) followed the elucidation of the chemistry of muconic acids and their 
lactones by Elvidge etal. (Refs. 12, 13). Evans and Smith (Ref. 14) showed that only 
cis,cis-muconate (7), and not its stereoisomers, can be converted into 3-oxoadipate (10) 
by extracts of benzoate-induced bacteria and, in collaboration with Linstead and Elvidge 
(Ref. 15), they reported that such extracts can also form 3-oxoadipate (10) from 
muconolactone (8). The intermediary of this lactone (8) was confirmed by Sistrom and 
Stanier (Ref. 16) who separated the enzymes of Pseudomonas fluorescens, which 
convert cis,cis-muconate (7) into 3-oxoadipate, into two fractions. One fraction catalyzed
5
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OH
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the formation of (+)-muconolactone (8) from ds,ds-muconate (7), the other converted 
(+)-muconolactone (8) into 3-oxoadipate (10).
The closely related, protocatechuate (11) can be transformed enzymically into 3- 
carboxy-d.y,d.s-muconate (12), which was first identified by MacDonald et al. (Ref. 17). 
They also found that only the cis,cis-isomer of the tricarboxylic acid (12) was converted 
into 3-oxoadipate (10) (Scheme 4). The microbial degradation pathways provided an 
interesting example of evolutionary divergence. In bacteria, 3-carboxymucononate (12) 
was metabolized to 4-carboxymuconolactone (13), which was then decarboxylated 
enzymically resulting in the formation of the enol-lactone (9) (Scheme 5). Slow, non- 
enzymic decarboxylation gave muconolactone (8). The enol-lactone (9) is the first 
common intermediate in pyrocatechol (1) and protocatechuate (11) metabolism. The enol- 
lactone (9) is then hydrolysed enzymically to give 3-oxoadipate (10) (Ref. 5).
Gross et al. were the first to show, using Neurospora, that the reactions of the 
carboxymuconate (12) branch deviate in fungi from those in bacteria (Ref. 18). 
Lactonisation of 3-carboxymuconic acid (12) yielded the 3-carboxymuconolactone (14), 
which was subsequently converted into 3-oxoadipate (10) via the enol-lactone (15) 
(Scheme 6). The steps leading from the lactone (14) to the adipate (10) will be elucidated 
later (see Sec. 1.3.2).
6
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Alternatively, 4-methylpyrocatechol (20), derived from toluene (17) and its 
derivatives such as /7-toluic acid (19) and p -cresol (18) which occur in petroleum and 
industrial wastes, can be transformed microbially into 3-methyl-c/j,czj-muconic acid (21) 
(Scheme 7). Thereafter, the catabolic pathways (Scheme 8) in bacteria and fungi diverge, 
in the manner described before for 3-carboxymuconate (12). In fungi, cyclisation of 3- 
methylmuconate (21) gives 3-methylmuconolactone (23) (Scheme 8f), which is 
isomerised to 3-methyl-4-oxoadipate (24), a catabolic source of pyruvic and acetic acid 
(Ref. 19). The details of the transformation (23) to (24) have yet to be elucidated. Until 
recently, it was thought that the catabolism of 3-methylmuconate (21) in bacteria was 
necessarily incomplete. The cyclisation of compound (21) gives 4-methylmuconolactone 
(22), which is not susceptible to delactonization in a manner analogous to that by which 
the unsubstituted compound (8) and 4-carboxymuconolactone (13) are degraded,
7
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because it lacks the proton or carboxy group at C(4) to allow further transformation. 
Indeed, in bacteria such as Pseudomonas putida the 4-methylpyrocatechol (20) is subject 
to unproductive orf/io-cleavage with accumulation of 4-methylmuconolactone (22) as a 
'dead-end metabolite' (Refs. 20, 21) (Scheme 8b). However, the discovery (Ref. 22) that 
certain nocardioform actinomycetes (bacteria) could convert 4-methylmuconolactone (22)
OH d 7 )
(18) (19)
OH
OH
C 02H c h 3
(2 1 .
(20)
Scheme 7.
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into the characteristic fungal lactone (23), led to the identification of a new type of 
enzymic transformation. A strain of Alcaligenes eutrophus (Ref. 23) and several 
nocardioform actinomycetes (Ref. 24) including Rhodoccus rhodocrous, all produce 
enzymes able to catalyse the isomerisation of the bacterial lactone (22) into the fungal 
lactone (23) and thereby overcome the bacterial 'block' (Scheme 8b*). These specialised 
bacteria have evolved a new strategy to allow complete catabolism of toluene derivatives 
by a methylmuconate route.
3 (dead-end product) — \ \
22) C02H b, bactena
C 02H c h 3
f, fungi
b*, specialised bactena
CC^H CH3
c h 3c o o h
o  c o 2h  2
c h 3c o c o 2h
+
c h 3c o 2h
Scheme 8.
1.2 ENZYMOLOGY OF THE MUCONIC ACID PATHWAY
1.2.1 Bacterial Enzymes
The enzymes involved in the metabolism of pyrocatechol and its derivatives have
9
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been extensively investigated. A few enzymes have been isolated from bacteria and fungi, 
and some have been purified and characterized. Each group of organisms has a 
characteristic type of enzyme. The metabolism of pyrocatechol and protocatechuate in 
bacteria provides good examples of the enzymology in the muconic acid pathways 
(Ref.8) (Scheme 9).
(1 ) Pyrocatechol 1.2-Dioxvgenase and Protocatechuate 3.4-
D ioxvgenase
Pyrocatechol 1,2-dioxygenase was originally purified from a Pseudomonas 
species and it was shown to be a dioxygenase, which can introduce molecular oxygen 
directly into pyrocatechol (1), with the formation of cis,cis-muconic acid (7) (Scheme 9) 
(Refs. 14, 25). In 1970, Varga and Neujahr (Ref. 26) isolated pyrocatechol 1,2- 
dioxygenase from a strain of Trichosporon cutaneum. The purified enzyme was 
homogeneous upon polyacrylamide gel electrophoresis and red in colour as a result of the 
association of two ferric ions with each molecule of haematic enzyme. Its molecular 
weight is 109,000 daltons as determined by gel filtration. The pH optimum is 8.0. This 
enzyme has a broad substrate specificity; besides pyrocatechol, it is able to cleave 
hydroxyl- and methyl substituted pyrocatechols. This enzyme has biochemical properties 
resembling those of similar enzymes isolated from other microorganisms (Refs. 27, 28). 
The analogous enzyme, protocatechuate 3,4-dioxygenase, was purified from extracts of 
Pseudomonas aeruginosa and crystallized by Fujisawa and Hayaishi (Ref. 29). It has a 
molecular weight of 70,000 daltons, and like pyrocatechol 1,2-dioxygenase, is deep red, 
because eight ferric ions are bound to each molecule of this enzyme. The X-ray structure 
was reported in 1984 (Ref. 30). Both dioxygenase contained non-heme iron as a sole 
cofactor.
(2) cis.cis-M uconate-Lactonizing Enzvme and M uconolactone Isom erase
10
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cis,cis-Muconate-lactonizing enzyme and muconolactone isomerase catalyze 
sequential reactions in the microbial dissimilation of c/s.cfs-muconate (7) via 3- 
oxoadipate pathway (Scheme 9). The enzymes are inducible in bacteria and the 
comparative study of the regulation of their synthesis in different bacterial genera has
C02H
Protocatechuate 
3, 4-dioxygenase
3-Carboxymuconate 
lactonizing enzyme 
(cycloisomerase)
CO2H CO2H
k A
( 12 ) c ° 2h
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1,2-dioxygenase
(8) O
4-Carboxymuconolactone 
decarboxylase \
3-Ketoadipate enol-lactone 
hydrolase
(9) O
(7) CO2H
Muconate lactonizing 
enzyme
(cycloisomerase)
CO2H
Muconolactone
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O CO2H 
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Scheme 9.
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been the subject of intense investigation (Refs. 8, 31, 32, 33). In 1973, Meagher and 
Omston (Ref. 34) reported an improved method for direct isolation of a large quantity of 
pure n\s,cw-muconate-lactonizing enzymes and muconolactone isomerase from crude 
extracts of Pseudomonas putida by DEAE-cellulose chromatography. Both enzymes were 
crystallized after extensive dialysis against distilled water at 5 °C. The subunit size of the 
cw,c/5-muconate-lactonizing enzyme is approx. 40,000 daltons, and the amino terminus 
of this enzyme is threonine. The crystal structure of cis,cis-muconate lactonizing enzyme 
at high resolution (3A) was reported by Goldman et al. (Ref. 35) and Neidhart et al. (Ref. 
36). Muconolactone isomerase is composed of subunits of about 12,000 daltons. The 
amino terminus of the isomerase is methionine. The X-ray structure was analysed by 
Katz et al. (Ref. 37).
(3) 3-Carboxv-cis.cis-M uconate Lactonizing Enzvme and
4-Carboxvmuconolactone Decarboxylase
In procaryotes, 3-carboxy-di,c/s-muconate-lactonizing enzyme and 4-carboxy- 
muconolactone decarboxylase are also inducible; they catalyse reactions chemically 
analogous to those mediated by ds.ris-muconate-lactonizing enzyme and muconolactone 
isomerase respectively (Ref. 38) (Scheme 9). The 4-carboxy-c/s.as-muconate lactonizing 
enzyme was isolated, purified and crystallised by Patel et al .(Ref. 39) from the same 
strain Pseudomonas putida from which cis,cis-muconate lactonizing enzyme was 
obtained. They reported that these two enzymes possess similar molecular sizes (190,000 
daltons), subunit sizes (40,000 daltons), crystalline shape, and amino terminal 
sequences. Parke and Meagher (Ref. 40) reported that 4-carboxymuconolactone 
decarboxylase from Pseudomonas putida and muconolactone isomerase from the same 
strain are the products of homologous structural genes because they catalyse a similar 
reaction and have similar molecular sizes (93,000 daltons), subunit sizes (12,000 to
13,000 daltons) and crystalline shape (Scheme 9).
12
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(4 ) 3-Oxoadipate Enol-Lactone Hvdrolase
The 3-oxoadipate enol-lactone hydrolase can be isolated from many organisms, 
e.g. Acinetobacter calcoaceticus (Ref. 32) and Alcaligenes eutrophus (Ref. 41). Two 
forms of hydrolase exist, hydrolase I and hydrolase II. It has been shown that these two 
enzymes are subject to independent induction (Scheme 9). Its crystal structure was 
reported in Ref. 42.
1 . 2 . 2  Fungal Enzymes
Only a few enzymes have been isolated from fungi, among them, 3-carboxy-c/s, 
c/j'-muconate cycloisomerase from Aspergillus niger (Ref. 43). It has several features in 
common with the bacterial cycloisomerase. Both are inhibited by the tribasic anions, 
phosphate and citrate. Both have similar Km values for their 3-carboxymuconic acid 
substrates. Both have molecular weights of about 200,000 and both are precipitated 
between 0.3 and 0.5 M diammonium sulphate saturation. Both are acidic proteins but the 
fungal enzyme is much more sensitive to thermal inactivation than that from 
Pseudomonas putida.
1 . 2 . 3  Specialised Bacterial Enzymes: 4-Methylmuconolactone Methyl- 
isomerases
4-Methylmuconolactone methylisomerase was observed in a strain of Alcaligenes 
eutrophus in 1985 by Pieper etal.{Ref. 23). Recently, they isolated and purified one 4- 
methylmuconolactone methylisomerase over 700-fold, to electrophoretic and gel 
chromatography homogeneity, from a constructed derivative of Pseudomonas sp. B13, 
named Pseudomonas sp. B13 FR1 (pFRC20P), which contains the gene coding for this 
isomerase from Alcaligenes eutrophus JMP 134 (Ref. 44). It has a molecular weight of
40,000 daltons and consists of a single polypeptide. This enzyme is therefore a
1 3
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monomer. A similar enzyme was purified and characterized from a nocardioform 
actinomycetes Rhodococcus rhodocrous N75 by Bruce and Cain (Ref. 24). Preliminary 
purification of the isomerase was effected by heat treatment at 60 °C, which precipitated 
co-occurring proteins. Further purification was then achieved by successive ion-exchange 
chromatography, gel filtration, and gel electrophoresis. The enzyme was very thermo 
stable and had molecular weight of 75,000 daltons (Ref. 45). This enzyme consists of 
four identical subunits, thus in contrast with monomeric Pseudomonas sp. enzyme it is a 
tetramer. Both enzymes can be inhibited by thiol modifying agents, e.g. CUSO4, whereas
chelating agents have no effect, e.g. dithiothreitol. From the kinetic data obtained, they 
postulated that two different mechanisms might exist for these two enzymes in the 
conversion of 4-methyl- (22) into 3-methyl- (23) muconolactone (see Sec. 1.3.3).
1.3 STEREOCHEMISTRY OF SOME ENZYMATIC CONVERSIONS
1.3.1 Lactonization
In 1969, Avigad and Englard first reported that the muconate lactonizing 
cycloisomerase from Pseudomonas putida catalyzed the cycloisomerization of cis,cis- 
muconic acid (7) to the muconolactone (25) by syn addition of carboxyl group to the 
double bond (Ref. 46) (Scheme 11). The absolute stereochemical course of this reaction 
was determined by feeding of the c/.s,c/$-muconate (7) to Pseudomonas cultures in 
tritiated water (Scheme 11). 5-[3H]-Muconolactone (25) was obtained enzymically with
O
(2 2 )
A. eutrophus 
R. rhodocrous
Scheme 10.
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no tritium incorporated into the residual cis,cis-muconate (7). Chemical degradation of 
the stereospecifically labelled (+)-muconolactone (25) yielded tritiated L-malate (26) with 
the same specific activity; treatment of this with fumarate hydratase resulted in release of 
the tritium into the medium and formation of unlabelled fumarate (27). Since this enzyme 
catalyzes anti elimination of (S)-malate, the structure of the tritiated (+)-muconolactone 
(25) is (45, 5R) configuration, which implies syn addition of the carboxyl group to the 
double bond.
C02' <r° 2’
|. P. putida 3H » i.  ^
(7) O
(25) (45, 5R)
CO; CO2-
>h^ oh
H H 
(26) (25, 35)
anti furmarate
hydratase
HO2C
h^ h
(27)
c o 2h
Scheme 11.
In 1983, Ngai et al. (Ref. 47) carried out kinetic and equilibrium isotope-effect 
studies with n^ds-muconate cycloisomerase and found that the formation of a carbanion 
intermediate (28) from the muconolactone (8) is the rate determining step during the 
conversion of (+)-muconolactone (8) into cis,cis-muconate (7).
The corresponding carboxymuconate lactonization has been more widely studied. 
The absolute stereochemistry of the cyclization of 3-carboxy-d$,d$-muconate (29) into 
3-carboxymuconolactone (30) in the fungus Neurospora crassa was investigated by 
Kirby et al. in 1975 (Ref. 48) (Scheme 13). They incubated the deuteriomuconate (29) 
with a crude preparation of the lactonizing enzyme from N. crassa SY4a, isolated the
15
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resulting lactone (30), then decomposed this lactone (30) by successive treatment with 
ozone, manganese dioxide and formic acid-hydrogen peroxide to obtain the (25, 35 )-[3- 
H]malate (31). The absolute stereochemistry of this degradation product followed from 
its optical rotation, and the relative stereochemistry by comparison of its NMR 
spectrum with that of a standard. Thus the corresponding muconolactone (30) had the
O
slow
( 8 )
(28)
fast
(7)
Scheme 12.
(45,55) configuration. This analysis, a variation of the Avigad and Englard procedure, 
established the reaction as a sy/i-addition with the same stereochemical course as the 
muconate cycloisomerase.
CO2- CO2CO2 CO2
N. crassa tt»-L JL 
 ►
a v  ccv
H ^ O H  
D H
O
(30) (4S,5S) (31) (2S,3S)
Scheme 13.
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In contrast, Chari et al. (Ref. 49) have recently found that the enzymic cyclization 
of 3-carboxy-cw,c/,s-muconate (11), in deuterium oxide, gives the 4-carboxymucono- 
lactone (32) in both bacteria Pseudomonas putida and Acinetobacter calcoaceticus, and 
occurs by an anti addition (Scheme 14). The 4-carboxymuconolactone (32) formed is not 
stable due to its spontaneous decarboxylation, so the absolute configuration was 
determined by reductive trapping. Catalytic hydrogenation of the lactone (32), and 
chemical degradation of the resulting 5-[2H]homocitrate lactone (33) gave the 2- 
[2H]citrate (34). The absolute configuration of 2-[2H]citrate (34) was shown to be 
(2R,3S) from its NMR spectrum and hence the lactone (32) had the (4/?, 5R) 
configuration indicating that the lactonization proceeded by an anti addition.
The stereochemistry of the early stage of the methylmuconate pathway has 
recently been studied by Cain et al. (Refs. 50, 51). The absolute stereochemistry of two 
methylmuconolactones, (22) and (23), were first investigated in 1989. (±)-3-methyl- 
muconolactone (35) was prepared in quantity from 2-nitro-4-methylphenol (34) 
(Ref.52). The muconolactone (35) was separated from the by-product (36) and resolved 
by repeated crystallisation of the diastereomeric salts of (S)-(-)-2-phenylethylamine. Both
P. putida and 
A. calcoaceticus
H CO2  
(31) (4R, 5R)
O
CO2
(34) (2R, 3S) (33) (4S, 5R)
Scheme 14.
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salts were subjected to X-ray crystallographic analysis, thereby determining 
independently the absolute configurations of the corresponding lactone enantiomers. Each 
lactone was liberated from its salt and the (S)-(-)-lactone (35a) was found to be identical 
with the lactone obtained from an Aspergillus niger mutant. This finding was confirmed 
by feeding of 4-methylpyrocatechol (20) to Aspergillus niger that accumulated (-)-3- 
m ethylm uconolactone (23). The muconolactone (23) was then purified by 
recrystallisation and treated with (S)-l-phenylethylamine. The resulting salt was shown 
by X-ray analysis to be identical with the synthetic salt.
Me
OH
HO2C
Me
+ / = A
h o 2c  h n - a
(34)
(35) w (36)
(S) - PhCH(Me)NH2
O
X-Ray analysis 
of resolved salts
(35a)
Identical with 
fungal lactone
Me
+
(35b)
Scheme 15.
Determination of the absolute configuration of the bacterial 4-methyl- 
muconolactone (22) was achieved via the dilactone (38), a possible intermediate in the 
enzymic, lactone isomerization (22) to (23). This was confirmed by correlation with the 
3-methyl isomer (35a) (Scheme 16). The treatment of the (-)-lactone (35a) in aqueous 
sodium hydrogen carbonate (1 mol equiv.) with bromine in dichloromethane gave the (-)- 
bromodilactone (37). X-Ray analysis established the relative configuration and confirmed
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the absolute configuration at C-(5). The (-)-bromodilactone (37) reacted with tributyltin 
hydride (1.2 mol equiv.), in benzene containing azoisobutyronitrile (0.1 mol equiv.) to 
gave the (-)-dilactone (38). The NMR spectrum, m.p., and optical rotation of the 
synthetic (-)-dilactone (38) agreed well with those reported for the material formed by 
non-enzymic cyclization of natural (+)-4-methylmuconolactone (22), which must be 
assigned the 45 configuration (22).
Br2,NaHC03
Tributyltin hydride/AIBN
(22) c °2H
Scheme 16.
With the synthesis and stereochemistry of the appropriate substrates established, 
attention was turned to the stereochemistry and mechanism of the enzymic reactions of the 
methylmuconolactone pathways (Scheme 17). Trideuteriopyrocatechol (39) was used as 
a substrate to determine the stereochemistry of the lactone formation in a typical fungus 
Aspergillus niger, and in the strain of bacterium Pseudomonas putida (ATCC 12633) 
used in the studies on the classical muconate and carboxymuconate pathways. The 
trideuteriopyrocatechol (39), prepared by exchange in D2O-DCI, was fed in batches to a
mutant strain of Aspergillus niger which lacked the enzyme muconolactone cyclo- 
isomerase and was known to accumulate 3-methylmuconolactone (23). The NMR 
spectrum of the resulting lactone (43) showed, as expected, that highly stereoselective 
cyclization had occurred. The absolute stereochemistry at C-(5) was determined using the
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rigid bromodilactone (44). Unambiguous assignment of the C-(4) methylene signals in 
the NMR spectrum followed from the near-zero, vicinal coupling between the trans 
protons 4 -H r and 5-H [dihedral angle H(5)-C(5)-C(4)-Hr(4) 99°]. The *H NMR 
spectrum of the bromodilactone (44) showed a signal, 8 2.89 (t, J  jj  o  2.8 Hz), 
corresponding to 4-H r, and the complementary NMR spectrum showed a signal, 8 
3.34 (t, J  fj, d  2.9 Hz), corresponding to 4-D§. Therefore enzymic cyclization in 
Aspergillus niger must have occurred by syn addition.
1.03,CH2Cl2,-70oC HOw ?
2.HNO3,H2O,90oC R°2 c
c h 3
t
CC^H CH3
P. putida
D C02H 
(41)
d\ V d
D C02H 
(40) A. niger
(43)
D Br2JMaHC03
C 02R
(42)
,-Br
O:
(44)
Scheme 17.
Similarly, the pyrocatechol (39) was fed to Pseudomonas putida (ATCC 12633). 
The absolute stereochemistry of the resulting deuteriated 4-methylmuconolactone (41) 
was established by oxidative degradation to the citramalic acid (42). The *H NMR 
spectrum of dimethyl monodeuteriocitramalates, having an unambiguously determined
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relative configuration, has been reported by Muhll et al. (Ref. 53). The degradation 
product (42, R=Me) was therefore esterified with diazomethane; the proton spectrum 
corresponded closely with that reported in the literature. Thus, cycloisomerization of 3- 
methyl-a\s,d5-muconate (40) in Pseudomonas putida proceeds by syn-addition to form a 
(4S)-lactone (41). This result contrasts unexpectedly with the anti cyclization of the 
carboxymuconic acid (12) in the same organism.
1.3.2 Conversion of 3-Carboxymuconolactone into 3-Oxoadipic Acid
In 1977, Hill et al. (Ref. 54) incubated the deuteriated 3-carboxymuconic acid
(45) with a cell-free preparation from Neurospora crassa to afford the 3-oxoadipic acid
(46) with, surprisingly, retention of both deuterium atoms (Scheme 18). Similarly, the 
monodeuteriated acids, (47) and (50), gave monodeuteriated products (48) and (51). 
The intermediate carboxymuconolactones were not isolated.
pn TT nA T
N. crassa
enzymeD CO2H 
(45) (46)
c o 2h  c o 2hw ccbH HN. crassa HOOC
D CC^H 
(47)
enzyme
O CC^ H 
(48)
CC^H
(49)
CC^H CC^Hsv DN. crassa ►  h o o c
H CC^H 
(50)
enzyme
O CC^H 
(51)
CC^ H
(52)
Scheme 18.
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When the oxoadipic acid (49) enzymically obtained from the muconic acid (47) 
was degraded with aqueous alkali, the resulting 2-deuteriosuccinic acid (49) had the 
configuration shown in Scheme 18. This was established by comparison of the optical 
rotation at various wavelengths with that of a standard. Thus the product (49) was (S)- 
(+)-2-deuteriosuccinic acid. In the complementary experiment, the muconic acid (50) was 
converted via (51) into (/?)-(-)-2-deuteriosuccinic acid (52). Incubation of an equal 
mixture of dideuterio and diprotio muconic acid gave 3-oxoadipic acid containing equal 
amounts of dideuteriated and diprotio species (mass spectral analysis). Thus, migration of 
deuterium must be intramolecular. These results strongly suggested that the first step in 
the enzymic degradation of the intermediate carboxymuconolactone (14) involves a 1,3- 
suprafacial migration of hydrogen (or deuterium) (Scheme 19), probably effected by a 
basic group on the enzyme, to form an enol-lactone (15). Hydrolysis of (15) and 
decarboxylation of the 3-keto-acid (16) would complete the process. All attempts to 
separate this multifunctional enzyme into components with different activities have failed 
and, so far, the postulated intermediates ( 15) and (16) have not been detected (Ref. 55). 
Apparently, the eukaryotes have evolved a more sophisticated catalytic system than the 
prokaryotes for the degradation of 3-carboxymuconate (11).
?°2' CO2*
O CO2- 
( 10 )
O CO2 
(16)
Scheme 19.
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Recently, a similar 1,3-proton shift has been shown to occur in the reversible 
interconversion of the parent muconolactone (54) with the enol-lactone (53) (Scheme 20) 
(Ref. 56), since the equilibrium favours the former, it was necessary to prove that 
migration occurred in the direction (53) (54). The carboxylactone (32) was formed
enzymically in deuterium oxide from (11) and incubated with the decarboxylase and 
isomerase enzymes. The successive reactions were monitored directly by NMR 
spectroscopy. Eventually, a simple spectrum indicated near quantitative formation of the 
(4S,5/?)-2,5-dideuteriomuconolactone (54). The lack of a significant resonance for 2-H 
(6 6.02) established a nearly exclusive proton transfer during the transformation (53) => 
(54). The final spectrum also confirmed the stereochemistry at C-(5) as R since an 
identical, asymmetric collapse of the C-(5) AB quartet was observed for the reaction of 
c is ,c is -muconate (11) with the cycloisomerase, which yielded (4S,5/?)-5- 
deuteriomuconolactone. The stereochemistry at C-(2) in enol-lactone (53), formed
CCV H
C02' CCV 
( 11 )
decarboxylase isomerase
3-carboxymuconate
cycloisomerase
D2O
H
(53) (2R, 5R)
Scheme 20.
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quantitatively from 4-carboxymuconolactone (32) by decarboxylase, was determined 
unambiguously by NMR spectroscopy and thus had (2R,5R) configuration. 
Therefore the intramolecular 1,3-shift of deuterium is almost certainly syn rather than 
anti.
There are therefore two examples of 1,3-proton shifts shown to occur in the 
muconic acid pathways, namely, (55) <=> (56), where R = H or CO2'  (Scheme 21). A 
similar shift is involved, with the same absolute stereochemistry, in the interconversion of 
the aconitic acids (57) and (58), although here there is almost complete exchange of the 
migration proton with the medium (Ref. 57).
(55)
CO2 f
(56)
( H* retained in molecule)
R = H or C 02
cf.
CO2H c o 2h  *
h°2c  J L  HO2C J L  J 1
•hY V  — —  y > r H
H CO2H 
(57)
H CO2H
(58)
( H * exchanges with medium)
aconitic acid
Scheme 21.
1.3.3 Conversion of 4-Methylmuconolactone (22) into
3-Methylmuconolactone (23).
It was found that the bacterium Alcaligenes eutrophus and several naturally 
occurring nocardioform actinomycetes including Rhodococcus ruber, all produced an 
enzyme able to catalyze the transformation of the 4-methyl-lactone (22) into the 3-methyl-
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lactone (23) (Scheme 22). This has led to the investigation of a new type of mechanism 
for enzymic transformation.
Scheme 22.
Using Rhodococcus rhodocrous N75, a nocardioform actinomycetes, Bruce et al. 
(Ref. 45) showed that this bacterium contains a novel enzyme which has the property of 
catalysing the conversion of 4-methylmuconolactone into its 3-methyl isomer. They 
isolated and purified this methylisomerase and showed it to be highly specific with 
respect to the interconversion of its substrates (Scheme 23). This enzyme only accepts 
(+)-(4S)-4-methylmuconolactone (22), the putative isomerization intermediate 1- 
methyldilactone (38), and simple dilactone (59) as substrates, and yielding (-)-(4S)-3- 
methylmuconolactone (23) and (S)-muconolactone as product. The dilactone (59) has a 
higher turnover rate (2.2 times higher) than 4-methylmuconolactone (22) itself. (+)- 
Muconolactone (8) is a moderately effective, competitive inhibitor while the 
dibromodilactone (60) is a strong irreversible inhibitor. The transformation (22) => (23) 
proceeds quantitatively, although in principle it should be reversible.
Significantly, the purified enzyme exhibited no activity towards either the cis,cis- 
or the 2-cisA-trans- isomer of 3-methylmuconic acid; neither were they effective 
competitive inhibitors. This excluded the possibility that the interconversion of the 4- 
methyl- to 3-methylmuconolactone first involved ring opening followed by recyclization 
in the opposite sense either directly or after isomerization to the 3-methy\-2-cis-4-trans- 
muconate. From kinetic data obtained with this enzyme, Bruce et al. postulated that a 1- 
methyldilactone (38) was an intermediate in the overall isomerization, but perhaps 
enzyme-bound, linked to a thiol group at the active site (Scheme 24). This would account
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Substrates
Inhibitors
(2 2 )
CH3 j *
Scheme 23.
O
for the extreme sensitivity of the enzyme to heavy metals and thiol reagents. However the 
stereochemistry and mechanism for closure and opening of the dilactone (38) remained to 
be elucidated.
CO2H
(2 2 )
O
O
c h 3
o
o
H
(38)
Scheme 24.
CO2H ? H3
(23)
In contrast with the mechanism of Bruce et al, Pieper et al. (Ref. 44) postulated 
somewhat different mechanism for this interconversion of 4-methyl- to 3-methyl- 
muconolactone catalysed by the similar isomerase isolated from their organism 
Pseudomonas sp B13 (pFRC20P). They excluded the possibility of involving either 
methylmuconate (21) or the methyldilactone (38) as free intermediates, because (1)3- 
m eth y l-m ,c /5-muconate (21) was not a substrate for the enzyme, and (2) the 1- 
methyldilactone (38) was converted more slowly into 3-methylmuconolactone (23) than 
was 4-methylmuconolactone (22) itself. Kinetic data also showed that non-covalently
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enzyme-bound l-methyldilactone is unlikely to be an intermediate in the overall reaction. 
By analogy with the analysis of Ngai et al. (Ref. 49), they suggested that the enzymic 
conversion of 4-methyl into 3-methyl muconolactone, (22) => (23), takes place through 
the reaction steps a-d (Scheme 25), similar to those described by Ngai et al. for the 
cycloisomerization of cis, ris-muconate (7) to corresponding muconolactone (8). The 1- 
methyldilactone (38) could be directly isomerized to 3-methylmuconolactone (23) (step 
e-d) or transformed into 4-methylmuconolactone (22) (step f and g). Z represents an OH 
group or an enzyme nucleophile, perhaps the thiol group.
,coo- ,COO
O ( 2 2 ) O
OO
(38)
O
ooc
Scheme 25
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1.4 THE PROPOSED RESEARCH PROJECT
The novelty of the methylisomerase reaction (22) to (23) prompted us to 
investigate the stereochemistry and mechanism of this isomerization using the enzyme 
from Rhodococcus rhodocrous. Two mechanistically distinct classes of pathway merit 
consideration for this enzyme-catalysed isomerization of (4S)-4-methylmuconolactone 
(22) as shown in Scheme 26.
O:
H
(38)(22) C° 2H (23) O
HO HO
Scheme 26.
In pathway a, protonation of the lactone carbonyl group of the substrate (22) 
might be followed by a 1,2-shift of the methyl group from C-(4) to C-(3) to give the 
oxygen-stabilised carbocation (61). Loss of a proton from C-(3) would then generate the 
hydroxyfuran (62) [a reverse 1, 2-shift of the hydrogen would produce the inappropriate 
R- configuration at C-(4)]. Enzyme-catalysed reprotonation of (61) at C-(4) would afford 
the lactone tautomer (23). The alternative pathway b cannot involve initial ring opening to 
give either cis,cis- or 2-ris,4-/ra/w-3-methylmuconic acid as a free intermediate, since, as 
explained before, neither acid is a substrate for the enzyme (Ref. 45). Consequently the 
simplest pathway not involving an enzyme-bound intermediate proceeds by initial ring
2 8
PARTI CHAPTER 1: INTRODUCTION
closure to give the dilactone (38). Ring-opening in the alternative sense would then give 
the lactone (23) having the (4S)-configuration demanded by a c/s-ring fused intermediate. 
In support of pathway b, the dilactone (38) was shown to be an effective substrate for 
the enzyme, as was the parent dilactone (59) as described in the proceeding Sec. 1.3.3. 
Also, the dilactone (38) was transformed faster than the substrate (22).
To explore the mechanism and stereochemistry involved in the muconic acid 
pathways, the present investigation therefore had as its first priority the design of 
experiments to distinguish unambiguously between the two classes of pathway illustrated 
in Scheme 26 and to establish the relative stereochemistry (syn or anti) of lactone ring 
closure and opening diagnostic of the pathway b. To this end, the deuterium labelled 
compounds (63) and (64) were fed to Pseudomonas putida to give the optically active 
lactones (65), and (66) (Scheme 27). The latter was chemically converted into dilactone 
(67). These three compounds (65), (66), and (67) were used as substrates for the 4- 
methylisomerase.
O ch3
o
C02H
( 66 )
Scheme 27.
In a separate study, the stereochemistry of c/s,c/s-muconic acid cycloisomerase in 
fungi was determined for the first time, to complete the study of the set of 6
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cycloisomerase enzymes (3 in bacteria and 3 in fungi). As a consequence, the fully 
deuteriated pyrocatechol (68) was fed to the mutant fungus Aspergillus niger, which 
accumulates muconolactone.
As described in Sec. 1.2.3 and Sec. 1.3.3, the dibromodilactone (60) is an 
irreversible inhibitor of the methylisomerase, and the inhibition probably involves a thiol 
group in the enzyme, which can be inhibited by heavy metal ions. The following 
compounds, shown in Scheme 29, were designed and prepared to be tested as new 
inhibitors. The dibromo compounds (70), (73) and known inhibitor (60) were reacted 
with thiol compounds, benzyl mercaptan and cysteine, to study the inhibition mechanism 
chemically.
D
E O,D A. niger
D OH
D CO2H
OH
(68) (69)
Scheme 28.
Br
( ± ) 0 ;0 (±)0 o
(70) (71)
H CH3
(72)
H CH3
(74)(73)
Scheme 29.
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Some other structurally modified substrates (75) to (80) were also made to 
explore the shape and the size of the active site of the methylisomerase.
D CO2H CH3 c °2 H
(76) (77)
C2H5 .H CH3 j H
sVCH3 O ^ p ^ i H  O ^ p ^ /T iH
{±) o ^  JT 7=0 (±) 0=^ JT /= o
CH3 C02h  h  c h 3
(78) (79) (80)
Scheme 30.
The compounds (81) and (82) (Scheme 31) were prepared to test as precursors 
for both the bacterium Pseudomonas putida and the fungus Aspergillus niger this time, to 
explore the shape and size of the active site of the dioxygenase and cycloisomerases.
C2H5
Scheme 31.
Finally, the non-enzymic cyclization of the muconolactone (8) and 4-methyl- 
muconolactones (22) was reported (Refs. 20, 68). The same phenomenon was observed 
for the 4-ethylmuconolactone (76) by the author. The cyclization of 3,4-dimethyl- 
muconolactone (77) under various conditions was studied as well.
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CHAPTER
___________________  TWO
RESULTS AND DISCUSSIONS
This chapter presents the results and discussions of experiments designed to 
elucidate the muconic acid pathways. Chemical synthesis of the substrates and 
intermediates required for biological investigations is discussed in Sec. 2.1. Sec. 2.2 
then describes a set of optically active muconolactones prepared biologically from the 
pyrocatechol derivatives using both bacteria and fungi. In Sec. 2.3, attention is focused 
on the elucidation of the mechanism and stereochemistry of the muconic acid pathways by 
using the data from the experimental results.
2.1 CHEMICAL SYNTHESIS
2.1.1 Full Deuteriation of Pyrocatechol
Deuterium chloride is a useful agent which can replace hydrogen with deuterium 
in activated aromatic rings. Cain et al. (Ref. 51) reported a simple method to fully 
deuteriate 4-methylpyrocatechol (20), by exchange in 4 M deuterium chloride solution at 
90 °C for 2 h (Scheme 32). The deuterium chloride solution was prepared in a similar 
way to that described by Thomas et al. (Ref. 59). The required amount of thionyl 
chloride was added to an access of deuterium oxide at 0 °C, and the sulphur dioxide 
which formed was swept out of the solution by dry nitrogen.
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SOC12 + D2O 2 DC1 + S02♦
DCI/D2O  
^ O H  9 0 ° C' 2 h  D
Scheme 32.
Likewise, pyrocatechol (1) itself was deuteriated in 4.1 M deuterium chloride 
solution at 90 °C overnight (Scheme 33). The purity of the product was determined by 
NMR spectroscopy. The spectra of the starting material (1) and product (68) were 
obtained at the same concentration and the integration of the residual aromatic proton 
showed that the 3,4,5,6-tetradeuteriopyrocatechol (68) was almost fully deuteriated.
DC1 /  DjO
90 °C, 18 h
( 6 8 )
Scheme 33.
2.1.2 Three Monodeuteriated 4-Methylpyrocatechols
(1) 4-M ethvl-r3-2H1pvrocatechol (63)
4-Methyl-[3-2H]pyrocatechol (63) was prepared from isovanillin (83) as follows 
(Scheme 34). Although in isovanillin (83) the positions ortho and para to the phenolic
33
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CHO
BryAcOH
CHO CHO
OH OH
OCH3
(84)
OCH3
(85)
CHO CHO
AlCl3/pyridine/CH2Cl2 Pd-C/H2/Et3N/CH3OH
OH OH
OH OH
(86 )
CH3
U .D
Pd-C/H2/H+/EtOH
6
(87)
Scheme 34.
hydroxyl group are strongly deactivated by the the aldehyde group towards electrophilic 
substitution, the deuteriation under the normal conditions still occurred, but was slow. 
The exchange was more rapid at position 2 than at position 6 and was not observed at 
position 5 (Ref. 60). To obtain pure 2-deuterio-product the position 6 was protected by 
bromination. The bromination of isovanillin (83) by bromine in acetic acid gave 2- and 6- 
bromoisovanillin, which were separated by repeated recrystallisation (Ref. 61). Then 6- 
bromoisovanillin (84) was deuteriated with deuterium oxide containing triethylamine as 
catalyst under gentle reflux under nitrogen overnight. The *H NMR spectrum of the 
product showed that complete deuteriation had occurred (Ref. 60). The deuteriated 
compound (85) was demethylated with aluminium chloride in dichloromethane 
containing pyridine under reflux overnight to give 2-deuterio-6-bromoprotocatechuic
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aldehyde (86) (Ref. 62). As Gallemaers et al. (Ref. 63) found that compound (88) was 
dechlorinated by hydrogenation over palladium-carbon and triethylamine under 
atmosphere pressure (Scheme 35), 2-deuterio-6-bromoprotocatechuic aldehyde (86) was 
likewise debrominated in similar conditions to yield 2-deuterio protocatechiiic aldehyde 
(87) in good yield without significant loss of deuterium. Hydrogenation of compound 
(87) over palladium-carbon in ethanol containing a catalytic amount of hydrochloric acid 
gave the target product, 4-methyl-[3-2H]pyrocatechol (63).
(2) 4 -M ethvl-f5-2HlDvrocatechol (96)
The first attempt at the preparation of 4-methyl-[5-2H]pyrocatechol (96) involved 
the route outlined in Scheme 36. Freudenberg et al. (Ref. 64) prepared [6-2H]vanillin 
(94) as an intermediate in the synthesis of deuteriated coniferyl alcohol. This compound 
was prepared in the same way using vanillin (90) as starting material. Successive 
acetylation and bromination of vanillin (90) gave 6-bromovanillin (92) (Ref. 65), which 
was refluxed with methanolic trimethyl orthoformate in the presence of ammonium nitrate 
to yield the dimethyl acetyl (93). The compound (93) was then treated with butyllithium 
in ether and the lithiated intermediate was decomposed with deuterium oxide. Hydrolysis 
then gave [6-2H]vanillin (94) (Ref. 66). Demethylation and hydrogenation of [6- 
2H]vanillin (94) under the normal conditions yielded 4-methyl-[5-2H]pyrocatechol (96). 
However, the deuteriation of compound (93) was difficult to control and gave a poor 
yield of rather impure product (94).
(88 ) (89)
Scheme 35.
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CHO CHO CHO
1. Br^aOAc/tyAcOH
OCH3
OH
(90)
HC(0CH3)3/NH4N03/CH30H
OAc
(91)
CH(OCH3)2
OH
(92)
CHO
1. BuLi/hexane/ether/I^O
OCH3 2. H20/H+ o c h 3
AlCl3/pyridine/CH2Cl2
OHOH
OHOH
(95)
Scheme 36.
(96)
To overcome these disadvantages and to shorten the procedure, [6- 
2H]protocatechuic aldehyde (95) was prepared directly from 6-bromovanillin (92) 
(Scheme 37). 6-Bromovanillin (92) was demethylated under the standard conditions to 
give 6-bromo-protocatechuic aldehyde (97). 6-Bromoprotocatechuic aldehyde (97) was 
dissolved in dry tetrahydrofuran and deuterium oxide containing 1 equiv. of triethylamine 
and debrominated by freshly prepared deuterium gas [from clean lithium metal and 
deuterium oxide] over 10% palladium-carbon at room temperature under atmospheric 
pressure. The product (95) was obtained in good yield and purity. This was again 
converted into the required product (96), without loss of deuterium.
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CHO CHO
AlCl3/pyridine/CH2Cl2 P d-C /D ^N /T H F
OH
OH
(92)
OH
(97)
CHO
D
^  Pd-C/H2/H+/EtOH
OH
OH
(95)
D,
OH
OH
(96)
Scheme 37.
(3) 4 -M ethvl-f6-2Hlnvrocatechol (641
This compound (64) had been prepared earlier by Kirby and Ogunkoya (Ref. 60) 
by hydrogenation of the benzylated intermediate (100) (Scheme 38), which was needed 
for another synthetic target. To determine the stability of nuclear deuterium under the 
normal conditions for benzylation and debenzylation of phenolic hydroxyl groups, they 
converted the monobenzylprotocatechuic aldehyde (98) into the monodeuteriated deriva­
t iv e ^ )  by refluxing it with deuterium oxide containing triethylamine. The resulting com-
CHOCHO
acetone
OH OH
(98) (99) (100)
EtOH
OH
OH
(64) 
Scheme 38.
3 7
PARTI CHAPTER 2: RESULTS AND DISCUSSIONS
pound (99) was benzylated with benzyl chloride and potassium carbonate to give the 
corresponding benzyl ether without loss of deuterium. Hydrogenation over palladium- 
carbon in ethanol containing a catalytic amount of hydrochloric acid then yielded 4- 
methyl-[5-^H]pyrocatechol (64).
A similar route was designed for the preparation of the pyrocatechol (64) using 
pyrocatechol (1) as starting material (Scheme 39). Pyrocatechol (1) reacted with 1 
equivalent each of benzyl chloride and sodium ethoxide to give the monobenzyl ether 
(101) (Ref. 67), which was separated from its diether by careful fractional distillation.
3-O-Benzylprotocatechuic aldehyde (101) was prepared by Reimer-Tieman formylation 
(Refs. 68, 69,70). Treatment of pyrocatechol O-monbenzyl ether (101) with chloroform 
under alkaline condition gave the aldehyde (98), which was separated from the O- 
monobenzyl ether (101) by chromatography. However the product was obtained in poor 
yield (19%). Deuteriation of this aldehyde (98) in deuterium oxide containing triethyl- 
amine, followed by hydrogenation over palladium-carbon in ethanol containing a catalytic 
amount of hydrochloric acid, under the usual conditions, gave the target product (64).
CHO
PhCH2Cl/EtONa/EtOH CHCl3/NaOH/EtOH
OCH2Ph
OH 
( 101 )
OCH2Ph
CHO
OH
OH
(64)OH(99)
Scheme 39.
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To shorten this route and get a better yield, the compound (64) was also 
synthesized from vanillin (90) (Scheme 40). Deuteriation of vanillin (90) in the usual 
way gave [5-2H]vanillin (102), which was demethylated by anhydrous aluminium 
chloride in dichloromethane in the presence of pyridine to give [5-2H]protocatechuic 
aldehyde (103). Hydrogenation of compound (103) yielded 4-methyl-[5-2H]- 
pyrocatechol (64).
CHO CHO CHO
OH
OH
(90)
OH
( 102 )
OH
(103)
EtOH
OHD
OH
(64)
Scheme 40.
2.1.3 Ethylpyrocatechol (81)
4-Ethylpyrocatechol (81) had been prepared earlier by Dr. D. R. Jaap (Ref. 71). 
Several different routes were considered for its preparation. Among them, one seemed 
most promising (Scheme 41).
OH OH
OH
(104) (105) (81)
Scheme 41.
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Cosgrove and Waters (Ref. 72) showed that a variety of monohydric phenols 
reacted with benzoyl peroxide in boiling chloroform to give monobenzoates of 
pyrocatechol derivatives (Scheme 42). Furthermore they showed that para- (106) and 
meta- (108) cresol gave the corresponding esters (110) and (111). The same products, 
(110) and (111), were obtained from meta-4- (108) and meta-5- (109)xylenol. They 
confirmed the structures of the products by independent synthesis. They suggested that 
with p-cresol (106) and /n-4-xylenol (109) the para-substituted esters, (110) and (111), 
are formed by molecular rearrangement of the initially formed me/a-substituted esters 
(112) and (113), possibly via the intermediate (114) and (115) (Scheme 43).
R = H (110)
OH
R = H (106)
R = CH3 (107) R = CH3 (111) 
Scheme 42.
R ^  OH
R = H (108)
R = CH3 (109)
CH3
R OBz
OH
R = H (112)
R = CH3 (113)
R
OH
C6H5
R = H (114)
R = CH3 (115)
OHR
OBz
R = H (110)
R = CH3 (111)
Scheme 43.
By reference to Dr. Jaap's work, 4-ethylphenol (104) likewise was heated under 
reflux in chloroform in the presence 1 equiv. of benzoyl peroxide for 6 h to give the
4 0
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monoester (105), which was then hydrolysed using aqueous sodium hydroxide. Pure 4- 
ethylpyrocatechol (81) (Ref. 75) was obtained by Kugelrohr distillation (Scheme 43).
2.1.4 4,5-Dimethylpyrocatechol (82)
Dimethylpyrocatechol (82) was prepared by the oxidation of 3,4-dimethylphenol
(115) with Fremy’s salt, followed by the reduction of the quinone (116) with potassium 
iodide, as shown in Scheme 44.
CH3 
Fremy's salt
O OH
OHO
(117) 
Scheme 44.
(82)
Fremy's salt (potassium nitrosodisulfonate) (118) was first prepared by Fremy 
about 150 years ago (Ref. 74). The modem methods for its preparation consist essentially 
of preparing the sodium or potassium salts of hydroxylamine disulfonic acid followed by 
oxidation with potassium permangante (Ref. 74a) (Scheme 45). Zimmer et a/.(Ref. 75) 
systematically reviewed oxidations with Fremy's salt. The overall stoichiometry of the 
oxidation of phenols was shown to be 1 equivalent of phenol with 2 equivalents of 
Fremy’s salt to give 1 equivalent of benzoquinone and 1 equivalent of dipotassium 
hydroxyimidodisulfate and 1 equivalent of dipotassium imidodisulfate (Scheme 46). The 
mechanism of this reaction has been studied in some detail (Refs. 76,77).
[o]
N aN 02 + NaHC03 + S02 ------ ► HON(S03Na)2— — 0 N( S03K)2
(118)
Scheme 45.
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+ 20N(S03Na)2
Scheme 46.
|| + H 0N (S03Na)2
5  + HN(S03Na)2
Stubenrauch and Knuppen (Ref. 78) reported that conversion of the 2- 
aminoestrone (119) to the corresponding 2-hydroxyestrone (120) was effected by 
oxidation with sodium metaperiodate in acetic acid and 0.1 N hydrochloric acid to give 
the corresponding orr/io-quinone, which was immediately reduced with potassium iodide 
in acetic acid and chloroform without prior isolation (Scheme 47).
(119) (120)
Scheme 47.
Accordingly, 3,4-dimethylphenol (116) was oxidised with Fremy's salt to give 
4,5-dimethyl-1,2-benzoquinone (117) (Ref. 78), which was reduced by shaking with 
potassium iodide in acetic acid-chloroform for 2 min. to form 4,5-dimethylpyrocatechol 
(82) (Scheme 44) (Ref. 78a)
2.1.5 3,4-Dimethylmuconolactone (77)
Brassard et.al. (Ref.79) synthesized 3,4-dimethylmuconlactone (77) in 1960 
from 4,5-dimethyl-1,2-benzoquinone (117), which was prepared from 3,4-dimethyl- 
phenol (Scheme 48). Oxidation of the 1,2-benzoquinone (117) in ether with a 10% 
excess of perphthalic acid for 4 d at 0 °C yielded cis, c/j-3,4-dimethylmuconic anhydride
4 2
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(1 2 1 ). Heating the anhydride (121) with water to 50 °C  formed 3,4- 
dimethylmuconolactone (77).
(117)
I  Fremy's salt 
H3C^ ^ 0H XX
O H2<V
(77) "O
H3C*
(116)
Scheme 48.
Pauly et a/.(Ref. 80) reported the preparation of racemic 3-methylmuconolactone 
(35) from the nitro compound (122) (Scheme 49). Thus the benzene ring of 2-nitro-p- 
cresol (122) can be directly cleared by concentrated sulphuric acid to form 3- 
m ethylm uconolactone (35). A similar route was adopted to prepare 3,4- 
dimethylmuconolactone (77) from 3,4-dimethylphenol (116) (Scheme 50). 3,4- 
Dimethylphenol (116) was carefully nitrated with concentrated nitric acid in acetic acid 
(Ref. 81). The 3,4-dimethyl-6-nitrophenol (123) was separated from the reaction mixture 
containing a dinitro compound by column chromatography (Ref. 82). The nitro­
compound (123) was heated with concentrated sulphuric acid at 110-115 °C for 2 h to 
form 3,4-dimethylmuconolactone(77), which was obtained by continuous extraction with
HO2C CH3 
conc. H2SO4 ^
no-5<c h^ \ /
(35) 0
Scheme 49.
c h 3
OH
( 122 )
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conc. H2S04
110- 115°C
Scheme 50.
HO2C
- (±)
H3C‘
ether after the reaction mixture had been diluted with water. A possible mechanism is 
shown in Scheme 51.
+ .OH
N = 0
HJ-0 C0  (o h  
*  i l  ^  I
ti 1
H3C +
H-rO ^H3C , - N - O H
h3c . '  V-x^U
+ .OH
HO2C VH3
HOHN
NH2OH
N=C
HOHN
Scheme 51.
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2.1.6 2-Bromo-(125) and 2,2- D ibrom o-butyrolactone (70)
These two products, (125) and (70), were prepared by a variation of Daremon's 
methods (Ref. 83) to get the pure compounds (Scheme 52). Butyrolactone (124) was 
heated to 100-130 °C with a catalytic amount of phosphorus tribromide. To it, 0.85 mol 
equivalent of bromine was added very slow during 4 h. The resulting mixture was heated 
between 100-130 °C for another 5 h. Repeated fractional distillation gave pure liquid 2- 
bromobutyrolactone (125). In a similar way, 3 mol equivalents of bromine was used to 
prepare 2,2-dibromobutyrolactone (70), the temperature being kept between 170-190 °C 
overnight. The quantities of bromine were critical, since it was possible to separate the 
lactone (124) from its monobromo derivative (125) by distillation, but impossible to 
separate the mono (125) and dibromo (70) derivatives in this way. The dibromo 
derivative (70) was crystalline.
2.1.7 The synthesis of dilactones
Unlike the unsubstituted muconolactone but like 3-methylmuconolactone, 3- 
ethylmuconolactone and 3,4-dimethylmuconolactone also could not be cyclised by acid 
catalysis to give the corresponding bicyclic dilactones. Instead bromodilactones were 
synthesised (Scheme 53). The lactones were dissolved in ice-cold water by addition of 
sodium hydrogen carbonate (lmol equiv.). Bromine (lmol equiv.) in dichloromethane 
was added and the two-phase mixture was stirred at room temperature for 4 h. Any traces
H
Br2 /PBr3
O
(70)
Scheme 52.
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of unreacted bromine were removed by addition of aqueous sodium thiosulphate. The 
dichloromethane layer and dichloromethane extracts of the aqueous layer were combined 
and dried. Evaporation of the organic solvents gave the bromodilactones in good yield. 
These were then suspended in dry benzene containing azoisobutyronitrile (0.1 mol equiv.) 
under nitrogen at room temperature. Tri-n-butyltin hydride (1.2mol equiv.) was added 
and the mixtures were stirred and warmed briefly to initiate reaction. After ca. 15 min. the 
bromodilactones had dissolved and the products had begun to crystallise out. After 1 h 
the crystals were collected and recrystallised from chloroform-hexane. The 
bromodilactones (127), (37), (71), and (72) and dilactones (59), (38), (79), and (80) 
were all prepared in this way. All were racemic.
HO2 C R
NaHC0 3 /B r2
K
° H ‘0  R = H R ' = H (127)
S0 R
R = H R' = H (8) I
R = H R’= Me (37)
R = H R' 11 f (35)
B113S11H 1
73 11 X R' = Et (71)
R = H R' = Et (126) r ' R = Me R* = Me (72)
R = Me R’ = Me (77)
R = H R’ = H (59)
IV
73 II X R' = Me (38)
R = H R' = Et (79)
R = Me R’
£11 (80)
Scheme 53.
Bromodilactones can be converted to the dibromodilactones (73), (60) and (74) 
via the intermediate bromolactones (128), (129), and (78), which need not be isolated 
(Scheme 54). The bromodilactones were suspended in an aqueous solution of sodium 
hydrogen carbonate (1 mol equiv.). The suspensions were stirred at room temperature for
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ca 1.5 h to produce clear solutions of the sodium salts of the bromolactone (128), (129), 
(78). Then bromine (lmol equiv.) in dichloromethane was added in the usual way to give 
dibromodilactones (73), (60), (74).
R = H R’ = H (127) 
R = H R' = Me (37) 
R = Me R' = Me (72)
HO2C
HO'
R
RR = H R' = H (128)
R = H R' = Me (129) 
R = Me R’ = Me (78)
Scheme 54.
R = H R' = Me (60) 
R = Me R' = Me (74)
Two other dilactones (65) and (76) were also prepared, for different purposes, 
from optically pure 4-substituted muconolactones (Scheme 55), following the same 
procedures as described above for the preparation of racemic dilactones.
O ^  . 0  *  H
NaHCQ3 / Br2
CO2H
R = CH3 R' = D (65) 
R = C2 H5 R’ = H (76)
Bu3SnH
R = CH3 R' = D (130) 
R = C2 H5 R’ = H (131)
R = CH3 R' = D (67) 
R = C2 H5 R '=  H (132)
Scheme 55.
2.2 BIOSYNTHESIS OF MUCONOLACTONES
Various pyrocatechol derivatives (Scheme 56) were fed to cultures of 
Pseudomonas putida for two reasons. First, the deuteriated 4-methylpyrocatechols (20),
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(63), (96) and (64) gave a set of optically pure labelled 4-methylmuconolactones, (22),
(65), (75), and (66), required to elucidate the stereochemistry and mechanism of the 
methylisomerase-catalysed reaction in Rhodococcus rhodocrous. Second, the ethyl (81) 
and dimethyl (82) derivatives were tested as substrates for the dioxygenase and 
cycloisomerase enzymes in Pseudomonas putida cultures by isolation of the 
corresponding derived muconolactone, (76), (133).
un
R 1 = R2= R3= H, (20) R 1 = R2 = R3= H, (22)
R 1 = D, R2= R3= H, (63) R 1 = D , R 2 = R 3= H, (65)
R2= D, R*=R 3 = H, (96) R2 = D, R1 = R3 = H, (75)
R3 = D. R1 = R2= H, (64) R3= D, Rl = R2= H, (6 6 )
OH 
(8 1  )
( 7 6 )
OH
( 8 2 ) ( 1 3 3 )
Scheme 56
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2.2.1 Pseudomonas putida
All the pyrocatechol derivatives were fed to the culture of Pseudomonas putida under the 
conditions employed successfully with the methyl pyrocatechol (Ref. 10) (Scheme 56). 
All substrates were fed, in three batches, to 3 day old cultures of Pseudomonas putida. 
After each batch, incubation was continued until a ferric chloride test showed that the 
pyrocatechol had been consumed. After 30 h, a ferric chloride test of the medium showed 
that there was negligible pyrocatechol left The entire culture media were extracted at pH 
7.5 with ether and the ether extracts were analysed by *H NMR spectroscopy. This 
showed that a small amount of non-acidic material, mainly pyrocatechols, had been 
removed. Then the culture media were adjusted to pH 2.5 and again extracted with ether. 
The ether extracts were analysed by ^H NMR spectroscopy also. The substituted 
muconolactones were identified as major products. The results of the feeding experiments 
are given in Table 1.
Table 1. Incubation in cultures of Pseudomonas putida
i yrocatechols Other pyrocatechols
(2 0 ) 3-D-(63) 5-D-(96) 6-D-(64) 4-ethyl- (81) 4,5-dimethyl (82)
Amount of 
catechol fed
800 mg 300 mg 373 mg 390 mg 450 mg, 
560 mg
560 mg
Incubation
time
30 h 30 h 30 h 30 h 30 h 30 h
Derived
lactones
(2 2 ) (65) (75) (6 6 ) (76) (133)
Yield of 
lactone
447mg 
44%
130mg
34%
90 mg 
19%
170 mg
34%
2*290mg, 
53%,42%
70 mg 
2 0 %
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2.2.2 Aspergillus Niger
Several pyrocatechols were also fed to Aspergillus niger under the same 
conditions employed in Ref. 23b for 4-methylpyrocatechol (20), which can be converted 
into 3-methylmuconolactone (23) (Scheme 57). The ethyl derivative (81) was tested as a 
substrate for the dioxygenase and cycloisomerase enzyme, and the fully deuteriated 
pyrocatechol (68) was used to determine, for the first time, the stereochemistry of the 
cycloisomerase enzyme in a fungus. The flasks containing fungi culture were incubated. 
The utilization of glucose was monitored by UV spectrometry (Ref. 84). When almost all 
the glucose had been consumed, the substrates were fed, in two batches, to the cultures 
of A. niger. The pH was remained at 5.5. After about 44 h, the cultures were adjusted to 
pH 7.2 and extracted with ether to remove non-acidic materials. Then the cultures were 
adjusted to pH 2.0 and again extracted with ether. The ether extracts were analysed by *H 
NMR spectroscopy. 3-Substituted muconolactones or muconolactone itself were the 
major products (Table 2).
R
OH
R = CH3 (20) R2= CH3 (23)
R = C 2 H5 (81) R2 = C 2 H5 (134)
D
OH
( 6 8 )
( 6 9 )
Scheme 57.
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Table 2. Incubations in cultures of Aspergillus niger
[3,4,5,6 -^H] -pyrocatechol 
(6 8 )
4-Methylpyrocatechol
(2 0 )
4-Ethylpyrocaterchol
(81)
Amount of 
pyrocatechol fed
515 mg 481 mg 475 mg
Incubation time 46 h 44 h 44 h
Muconolactones ................. m .................. ..................(23).................. (134)
yield of lactone 290 mg 60 mg 30 mg
56% 13% 7 %
2.3 NEW STEREOCHEMISTRY AND MECHANISM OF MUCONATE 
PATHWAYS
2.3.1 4-Methylmuconolactone (22) to 3-M ethylmuconolactone (23)
To clarify the two, mechanistically distinct mechanisms proposed in Sec. 1.4., a 
set of deuteriated 4-methylpyrocatechols was synthesised to serve as precursors for the 
correspondingly labelled 4-methylmuconolactones (Scheme 58). The preparation of (64) 
and (63) was discussed in Sec. 2.1.1. These two precursors, (64) and (63), were fed 
separately to cultures of Pseudomonas putida to afford the lactones (66) and (65) 
respectively. The monodeuterio 4-methylmuconolactone (66) and (65) were designed to 
test the possibility of methyl migration (Scheme 27, pathway a) during the isomerisation
(22) => (23). The lactones (66) and (65) were taken to Professor Cain's laboratory in
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Newcastle by Dr. G. V. Rao, who carried out incubation studies with the isomerase 
enzyme from Rhodococcus rhodocrous, with the following results.
O CH3
D OH D
(66 )
o  £ h I j H
CO2H
(65)
o  c h 3
Scheme 58.
If methyl migration were to occur, as indicated in Scheme 27, pathway a, 
compound (66) would give the 2-deuterio derivative (137) [although, conceivably, 
deuterium loss might occur by exchange from the medium], and the compound (65) 
would give the (5S)-5-deuterio derivative (138) (Scheme 59). However, these products 
(137) and (138) were not identified in the actual methylisomerase tests. When the 2- 
deuteriomuconolactone (66) was incubated with the isomerase enzyme, ispmerisation 
proceeded, essentially without loss of deuterium, to afford the (5/?)-5-deuteriolactone 
(135) (Scheme 60). The NMR spectrum of (135) showed a strong signal, 8 2.50 
(dt, J  4,5 8.5 Hz J  h,D  2 4 Hz)» arising from the 5-pro-S-proton in (66), and only a
5 2
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O pruH CH3
D
( 66 )
CO2H
(137) 0
CH3
D
0
(65)
CO2H
(138) Y)
Scheme 59.
weak signal, 8 2.98 (dd, J  16.3 and 2.4 Hz), arising from the 5-pro-R-proton in the 
unlabelled lactone due to the incomplete deuteriation of the pyrocatechol. Because the
(66) and (135) had previously been established by unambiguous methods, it followed 
that the newly formed lactone ring in (135) must have arisen by anti addition of the 
carboxyl group to the 2,3-double bond of the substrate (66). Again, incubation of the 
(5S)-5-deuteriolactone (65) with the isomerase gave the unlabelled lactone (23), 
consistent with anti elimination to form the 2,3-double bond of the product. However, 
there remain the possibility that enzyme-catalysed exchange of deuterium in the lactone 
(65) had proceeded by ring opening.
stereochemical assignment of methylene signals in the *H NMR spectra of the lactone
isomerase
isomerase
Scheme 60.
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Finally the trideuteriolactone (41), prepared by Dr. G.V. Rao, gave the dideuterio 
product (136) (Scheme 61). The NMR spectrum showed signals at 8 2.49 (br s, 5- 
pro-S-H), and 5.87 (br s, 2-H). Thus, the deuterium labelling pattern confirmed the 
conclusions drawn from experiments with the monodeuteriuolactones (66) and (65).
-O( CO2H 9 H3
, isomerase
► h' d? '  7
D COjH ° \
(41) (136)
Scheme 61.
Clearly, these results exclude any possibility of isomerisation by a 1,2-methyl 
shift (e.g. pathway a, Scheme 27). On the other hand, if the dilactone (38) is an 
intermediate on the alternative pathway b, then the stereochemistry of hydrogen loss from 
the 8-methylene group should match that observed for the lactone (65) (Scheme 62). To 
test this, the monolactone (65) was converted chemically into the (8S )-8- 
deuteriodilactone (67)via the corresponding deuterio derivative of the bromodilactone 
(130). Incubation of the dilactone (67) with the isomerase gave the unlabelled lactone
(23). Similarly the trideuteriomonolactone (41), prepared by Dr. G.V. Rao gave the 
corresponding bromodilactone (139), which was debrominated to afford the 
trideuteriodilactone (140). This was a mixture of C-4 epimers since, as expected, radical 
debromination was not stereospecific. Consequently, incubation of (140) gave the (5/?)- 
4,5-dideuteriolactone (136) mixed with smaller amount of its (5S) epimer. Deuterium 
was again lost specifically from the 8-position of the dilactone (140) (Scheme 62).
To summarise, experiments with the deuteriated 4-methylmuconolactones showed 
that the enzymic isomerisation (22) to (23) cannot proceed via 1,2-migration of the 
methyl group (Scheme 27, pathway a). An alternative pathway (Scheme 27, pathway b) 
involving the dilactone or some equivalent, enzyme-bound intermediate, is indicated.
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Irrespective of the timing of steps, closure and opening of the lactone rings proceeds 
stereospecifically (> 95%) by anti addition and elimination reactions. Interestingly, this 
conclusion contrasts with the syn addition observed for the cyclisation of 3-methyl- 
cis,cis-muconic acid, in Pseudomonas putida to give 4-methylmuconolactone (22) and in 
Aspergillus niger to give 3-methylmuconolactone (23). The observed loss of deuterium 
from the dilactones (67) and (140) is consistent with their putative role as intermediates. 
However, there is at present no direct proof that the dilactone is a free intermediate in the 
isomerisation (22) to (23).
CO2H
(65) D (41)
Scheme 62.
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2 .3 .2  Stereochemistry of the Muconic Acid Cycloisomerase Reaction in
the Fungus Aspergillus niger
The first stereochemical study of the muconic acid pathway was reported in 1969. 
Using the cycloisomerase enzyme from the bacterium Pseudomonas putida, Avigad and 
Englard (Ref.46) showed that the cyclisation of cis,cis-muconic acid (7) in tritiated water 
proceeded by syn addition of the carboxyl group to the double bond to form tritiated (4S)- 
muconolactone (Scheme 11). For the sake of completeness, it was decided to determine 
whether the same stereochemistry applied in a typical fungus (Scheme 63). The 
Aspergillus niger that accumulates muconolactone (23) was selected. The 
tetradeuteriopyrocatechol (68), prepared from pyrocatechol (1) in Sec. 2.1.1., was fed to
D
OH
( 6 8 )
D CO2 H 
( 6 9 )
H CO2 H 
( 5 4 )
CH3 CO2H 
( 4 3 )
OH
( 3 9 )
*. lH NMR spectrum: 6(200 MHz, D2O, tert-butanol at 1.22)
7.54 (1H, s, 3-H), 5.32 (1H, d, /  8 .6 Hz, 4-H), 2.30 
(1H, d, J  8 . 6  Hz, 5-H) cited from Ref. 56.
**. 5-H at 62.76 (t, J 2.3 Hz) (D6 -Acetone) reported by Dr .G.V Jiao
Scheme 63.
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the culture of Aspergillus niger as described in Sec. 2.2.2. The *H NMR spectrum of the 
product (69) showed only a singlet at 82.69 (pH7-8) with fine splitting. This was 
compared with that of (4S, 5R)-2,5-dideuteriomuconolactone (54), which was described 
by Chari et al. (Ref. 58). This showed that the lactone (69) obtained was (4S,5S)- 
[2,3,4,5-^H4]muconolactone, i.e. the cyclisation of cis.cis-muconic acid (7) proceeds by
syn addition in the fungus. The product (43), obtained by Dr. G.V.Rao by feeding 
trideuterio 4-methylpyrocatechol (39) to the same organism, provided good evidence of 
the above observation (Scheme 63) (Ref. 53). The establishment of the absolute 
stereochemistry of compound (43) was discussed in Sec. 1.2.3.
2 .3 .3  The Influence of Substituents on the Enzymic Reaction in 
the bacterium  Pseudomonas putida
In preliminary experiments, Dr. D.RJaap (Ref. 73) fed 4-ethylpyrocatechol (81) 
to Pseudomonas putida cultures and isolated 4-ethylmuconolactone (76) in low yield. 
The lactone was not crystalline, and the optical rotation, [cx]d 7.9 and 19.7 0 in methanol, 
of specimens from two separate experiments differed. Both were lower than that, [a]j) 
32±2 ° (Ref. 22) in water, of (S)-4-methylmuconolactone (22). Consequently, this 
feeding experiment was repeated (see Sec. 2.2.1). The lactone (76) again failed to 
crystallise, and the optical rotation was still low, [a]£> 14.5 °. The NMR spectrum 
agreed with that reported by Dr. Jaap. To effect complete characterisation and to provide a 
new potential substrate for the methylisomerase enzyme, it was decided to convert this 
lactone (76) into the corresponding ethyldilactone (132) (Scheme 64). It is not certain 
that the amorphous ethyllactone (76) is optical pure, however the sign of rotation and that 
of the crystalline ethyldilactone indicate it is, as expected, predominantly the (S)-isomer.
4-Ethylpyrocatechol (81) and 4, 5-dimethylpyrocatechol (82) were tested in 
parallel with 4-methylpyrocatechol (20) as precursors for Pseudomonas putida, described 
in Sec.2.2.1., to explore the shape and size of the active site of the dioxygenase and
5 7
PART I CHAPTER 2: RESULTS AND DISCUSSIONS
cycloisomerase. Interestingly, 4-ethylpyrocatechol (81) gave lactone yields of 42%, 
which is similar to the yield of 44% for 4-methylpyrocatechol (20), while 4,5- 
dimethylpyrocatechol (82) had a lower yield of 20%. These results suggest that the 
bulkier ethyl group does not affect the enzymic reaction, but the two methyl groups 
sterically hinder the cyclase enzyme. The dioxygenase appears to accept the 
dimethylpyrocatechol as a substrate since there was very little unchanged substrate (about 
9%) recovered at the end of the incubation. The product 3,4-dimethylmuconolactone (77) 
failed to crystallise. The structure was established by comparing the NMR spectrum 
of the bacterial product with that of the racemic synthetic muconolactone, and more 
supply is required for the further analysis.
C2 H5
V-0 c 2 h<
CC^ H
(76)
, c 2 h 5
(131) 'O
(132) 'O
Scheme 64.
2 .3 .4  The Influence of Substituents on the Enzymic Reaction in 
the Fungus Aspergillus niger
To explore the shape of the active site of the dioxygenase and cycloisomerase, 4- 
ethylpyrocatechol (81) was fed to the fungus Aspergillus niger. The 4-methyl­
pyrocatechol (20) was fed in parallel to provide a comparison of the yields of the 
lactones. The corresponding yield for the parent muconolactone (69) was also a good
5 8
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guide to the relative efficiencies of conversion. The results from feeding experiments 
showed that the yields of lactone from tetradeuteriopyrocatachol (68), 4-methyl- 
pyrocatechol (20), and 4-ethylpyrocatechol (81) in this fungus were quite different 
(56%, 13%, and 7% respectively) indicating that bulkier alkyl groups make the 
pyrocatechols poorer substrates for the cycloisomerase enzyme systems because there 
was not much pyrocatechols (1%, 8%, and 11% respectively) recovered at the end of the 
incubation.
The structure of the product 3-ethylmuconolactone (134) was established by 
comparing the NMR spectrum of fungal product with that of the racemic 
muconolactone (126). Due to the dark colour there is not enough light going through the 
solution, and the optical rotation could not be obtained. More analysis could not be done 
with such a low yield of the product
2.3.5 The Non-enzymic Cyclisation of Muconolactones
In 1950, Elvidge (Ref. 13) found that an isomeric, none-acidic compound was 
formed as a by-product in the study of lactonisation of cis.cis-muconic acid. This 
compound (59) was reproducibly prepared by either prolonged treatment of cis.cis- 
muconic acid (7) with sulphuric acid at room temperature or refluxing cis,cis-muconic 
acid (7) with 50% sulphuric acid (Scheme 65).
H
Scheme 65.
Catelani et al. (Ref. 20) investigated the dilactonisation of both 4-methyl- and 3- 
methylmuconolactone and found that 4-methylmuconolactone (22) can easily cyclise in
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several ways (Scheme 66). Thus, distillation of the crude compound, boiling with 
concentrated hydrochloric acid followed by ether extraction, leaving the oily product for 
several weeks, or chromatography on silica, all caused cyclisation to produce the 
methyldilactone (44). But 3-methylmuconolatone (23) was unaffected by each of these 
treatments.
CH3
0=/ i o
r * o
o '
C - 0  H
H
( 2 2 )
' (38)
Scheme 66.
During the course of preparation of optically active 4-ethylmuconolactone (76), 
the author found that this lactone (76) cyclised spontaneously during storage at room 
temperature for several weeks (Scheme 67). Proof of the dilactone structure came from 
the following physiochemical features. The crystalline product had [a]o  -105 0 (c, 0.6, 
in methanol) and m.p. 138-139 °C. The IR spectrum showed neither bands of acidic 
hydroxyl groups nor those of a double bond. There was a very intense band at 1790 cn r 
1, due to the two saturated y-lactone groups. The *H NMR spectrum of compound 
showed the following signals; 8 1.0 (3 H, t, J  7Hz, CH2-CH3), 2.85 (2H, q, with fine 
splitting, J  7Hz, CH2-CH3), 2.68 and 2.98 (4 H, m, 8- and 4-H2) and 4.85 (1 H, m, 5- 
H ). The mass spectrum showed the molecular ion at m/e 170. These data were consistent 
with that obtained from the ethyldilactone (132), therefore they had the same structure.
1
H
r t -— » O
CH2 CH3  
O. ■
o  
r - o
H
(76)
Scheme 67.
(132)
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It was interesting to study the non-enzymic cyclisation of 3,4-dimethyl- 
muconolactone (77) (Scheme 6 8 ), which has the structural features both of 4-methyl­
muconolactone (22), which cyclises easily, and of 3-methylmuconolactone (23), which 
does not. Also cyclisation would provide a short route to the dilactone (80), which 
otherwise must be prepared (see Sec. 2.1.7) via the bromodilactone. Unfortunately, It did 
not cyclise under the following conditions:
(a) in CDCI3 containing 50 % CF3COOH at room temperature.
(b) in CF3COOH with heating under reflux.
(c) in 70% H2SO4 with heating under reflux.
(d) in 50% aqueous ethanol containing Amberlyst-15 as catalyst, at room 
temperature.
(e) adsorbed on silica gel HF254 in EtOAc at room temperature.
Conditions (b) and (c) led to loss of material. In all other cases the lactone (77) was 
unchanged.
O
(7 7 ) (80)
Scheme 68.
2 . 3 . 6  Chemical Model Studies for an Inhibitor of the Methylisomerase
In co-operation with Professor Cain we found that the dibromomethyldilactone 
(60) is a strong irreversible inhibitor of 4-methylmuconolactone methylisomerase. It was 
alreadly known that this enzyme was also inhibited by Hg2 + salts, so it was deduced that 
the inhibition might be related to the reaction with a thiol group on the protein. Several 
dibromo compounds were studied to test this idea chemically.
6 1
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The known irreversible inhibitor, dibromomethyldilactone (60) was firstly 
studied. It was treated with 2 equivalents of benzyl mercaptan in aqueous ethanol under 
reflux overnight (Scheme 69). The 200 MHz NMR spectrum of the crude reaction 
mixture showed that it was a mixture of debrominated product, bromomuconolactone 
(129, R=H), the ethyl ester (129, R=C2H5) (the ratio is about 3:7), and disulphide
(139). When the reaction was carried out with 0.9 equivalent of benzyl mercaptan at 
room temperature overnight, the spectrum showed that the reaction mixture apparently 
contains debrominated product (129, R =H), its ethyl ester (129, R=C2H5), unreacted
dibromodilactone (60) and disulphide (139). Further characterisation of the reaction 
product was not achieved. More interesting work was carried our with the thiol amino 
acid, cysteine, which is described as follows.
(60) +
SCH2Ph
I (139)
SCH2Ph
Scheme 69.
The dibromomethyldilactone (60) was first treated with 2 equivalents of the 
amino acid, cysteine (Scheme 70), in ethanol-water (1:1, v/v) at room temperature. The 
white precipitate that formed immediately was collected after 2 h and identified as cystine 
monohydrobromide (140) by *H NMR spectroscopy and mixed melting point 
determination. A reference specimen was prepared from cystine and hydrobromic acid. 
The filtrate was evaporated to dryness and the residual solid was recrystallised from 
chloroform. This solid was characterised as 2-bromo-'S-methyl-4-carboxymethyl-Aa -
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butenolide (129, R-H) from the following physiochemical features. It had the melting 
point 77-80 °C (from chloroform); m/e 235.9500 (19.5%), 233.9522. C7H7Br0 4
requires 235.9509, 233.9586. The IR spectrum has the corresponding absorbance for 
double bond and carbonyl group. The *H NMR spectrum, 8 1.62 (2H, s, 3-Me), 2.51-
3.18 (2H, AB part of ABX, /  18, 7 and 1 Hz, 5-H2), and 5.25 (1 H, dd, J  7 and 1 Hz, 
4-H).
O + 2 HS CH2CH(NH2)COOH
H
(60)
S CH2CH(NH2)COOH 
+ 1 * HBr
S CH2CH(NH2)COOH
(140)
Scheme 70.
Likewise the parent dibromodilactone (73) was also reacted with cysteine under 
the same conditions (Scheme 71). Again, the reaction occurred rapidly at room 
temperature. The water soluble product was characterized as 2-bromo-4-carboxymethyl- 
Aa -butenolide (128) by comparison with an anthentic sample.
U .Hr
( ± ) o
H
(73)
CC^ H
S CH2CH(NH2)COOH 
I * HBr
S CH2CH(NH2)COOH
(128) "  (140)
Scheme 71.
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The simplest dibromo lactone (70) was also treated with cysteine under the same 
conditions. No significant reaction occurred at room temperature even overnight. 
Therefore triethylamine (1 equiv.) was added to generate the more reactive thiolate anion. 
This time a complex mixture of products was produced slowly. Finally, the 
dibromolactone (70) was treated with 3 equivalents of cysteine and 2 equivalents of 
triethylamine (Scheme 72). After 4 h, the precipitate was filtered off and dried. It was 
identified as cystine by *H NMR spectroscopy and mixed melting point determination. 
The fitrate was evaporated to dryness and the water soluble residue was extracted with 
chloroform and methanol respectively. Evaporation of the chloroform gave triethylamine 
hydrobromide. Evaporation of methanol gave a light coloured solid. Although it could not 
be fully purified, it appeared to be the substituted lactone (141), presumably existing as a 
mixture of diastereoisomers.
Br
 J..»»iBr
I  \  + 2 Et3N + 3 HSCH2 CH(NH2)COOH
(7 0 )
H
\  %xvSCH2CH(NH2)COOH 
I — A SCH2 CH(NH2)COOH
( ± ) > 5 5 0  + | + 2Et3N * HBr
0  SCH2CH(NH2)COOH
(1 4 1 )
Scheme 72.
This was confirmed by treating 2-bromobutyrolactone (125) with 1 equivalent of 
cysteine and 1 equivalent of triethylamine (Scheme 73). The NMR spectrum and mass 
spectrum of the product closely resembled those of the foregoing product.
Presumably, the simple dibromodilactone (70) is also first reductively 
debrominated by the thiol, but the debromination is slower than the subsequent reaction 
of the bromolactone (125) with more cysteine. It is interesting that debromination with 
lactone ring opening, of the dibromodilactone, is much faster than the reaction of the
6 4
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H
+ Et3N + HSCH2CH(NH2)COOH
( 1 2 5 )
H
SCH2CH(NH2)COOH
+ Et3N * HBr
( 1 4 1 )
Scheme 73.
model dibromolactone (70). Indeed, the former reactions do not require any added base. 
It rem ains to be determined whether inhibition of the enzym e with the 
dibromomethyldilactone (60) also results in disulphide formation with liberation of the 
bromolactone (129).
2 .4  C O N C L U S IO N S
Investigations of muconate pathways were centered on the elucidation of the 
mechanism of and establishment of the stereochemistry of the muconolactone 4- 
methylisomerisation reaction. Experiments with labelled substrates showed that the 
enzymic isomerisation can not proceed via 1,2-migration of the methyl group. An 
alternative pathway involving the dilactone or some equivalent enzyme-bound 
intermediates is indicated. The analysis of the products obtained by incubating the 
corresponding labelled muconolactone to the methylisomerase from R hodoccus  
rhodocrous established the location and stereochemistry of the deuterium, thus showing 
that isomerisation had occurred with the formation of a new lactone ring by anti addition 
and the transformation was completed with the ring opening by anti elimination. The loss 
of deuterium from the labelled dilactone reinforces the status of the methyldilactone (44)
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as an intermediate in the methylisomerisation reaction. The same conclusiona were 
reached from Dr. G.V.Rao's supplementary experiments. These conclusions contrast 
with the syn addition observed for the cyclisation of 3-methyl-ds,ds-muconic acid (21), 
in Pseudomonas putida to give 4-methylmuconolactone (22) and in Aspergillus niger to 
give 3-methylmuconolactone (23). However, direct experimental evidence is still needed 
to decide whether the methyldilactone (44) is a free intermediate in the enzymic reaction. 
So far only 3 substrates have been tested for the methylisomerase of Rhodococcus 
rhodocrous.
Scheme 74.
A large set of mono- and di-lactones (Scheme 74) has already been sent to 
Newcastle to be tested as substrates or inhibitors for the methylisomerase. Moreover, the
( 7 6 )  C° 2H
( 7 5 ) ( 7 7 )
c h 3
( 7 1  )( 7 8 ) ( 1 2 9 )
(±)0 o (±)0
H H CH3
( 7 2 )( 7 9 ) ( 7 4 )
H CH3
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3-substituted monolactones, and the 3,4-dimethyllactone (77) will be tested with cell 
extracts able to degrade 3-methylmuconolactone. The dimethyllactone (77) is unlikely to 
be degraded, but it might act as a competitive inhibitor.
Attempts were made to correlate the thiol group with the enzyme inhibition 
chemically. The known inhibitor, dibromodilactone (60) can be debrominated by benzyl 
mercaptan. The debrominated product, bromomuconolactone (129) was obtained. When 
this dibromodilactone (60) was treated with cysteine under neutral conditions the 
debrominated product, bromomuconolactones (129), and the disulphide compound 
(139), cystine, were formed. The same outcome was obtained with the parent 
muconolactone (73). Whereas the simple dibromobutyrolactone did not react with 
cysteine under the same condition. Triethylamine was used as catalyst, the 
dibromobutyrolactone yielded the substituted lactone (141). These findings need to be 
confirmed by biochemical experiments.
A great deal still needs to be done to clarify the mechanism of this novel 
methylisomerase enzyme. For example, experiments with tritiated 4-methyl- 
muconolactone are planned to see if the methyldilactone can be detected as a free 
intermediate. Also, it will be interesting to use the tetradeuteriolactone (69), already 
prepared enzymically, to see if the enzyme will catalyse a ' virtual reaction', that is 
conversion of the parent muconolactone into itself (Scheme 75). Since the enzyme, 
fortuitously, operates in the anti mode, then this lactone would be converted into a 1:1 
mixture of the trideuteriated products (142) and (143). The composition of this mixture 
could be determined unambiguously by NMR spectroscopy and mass spectrometry.
( 1 4 2 )
Scheme 75.
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Little is known about the pathway leading from 3-methylmuconolactone (23) to 
metabolically useful products in fungi or the specialised bacteria. This will be a major area 
of investigation in the future.
Fully deuteriated pyrocatechol was fed, for the first time, to the fungus 
Aspergillus niger to give (45,55)-2,3,4,5-tetradeuterio muconolactone (69), which 
completed the study of the set of enzymes (3 in bacteria and 3 in fungi). The result 
demonstrated that in the fungus Aspergillus niger, the cyclisation of cis,cis-muconic acid 
proceeds via syn  addition of the carboxyl group the the double bond, The same 
stereochemical outcome has been achieved in previous published papers summarized in 
Sec.1.1.3.
The biosynthetic experiments with Pseudomonas putida showed that pyrocatechol 
with the larger alkyl group like ethyl does not effect its conversion into the corresponding 
muconolactone. But 3,4-dimethylpyrocatechol (82) gives a poorer yield of the 
corresponding muconolactone (133), which may be that either pyrocatechol with more 
alkyl-substituents is not readily cleaved by the dioxygenase enzyme which effects their 
conversion into the corresponding muconic acid or subsequent cyclisation to give 4-alkyl 
muconolactone is also retarded by more alkyl groups. The latter point could be tested by 
experiments with ds,ds-3,4-dimethylmuconolactone.
The feeding experiments with Aspergillus niger showed that 4-substituted 
pyrocatechols with larger alkyl group are not good substrates for the enzyme system. The 
larger the substituent the pyrocatechol has, the poorer yield of muconolactone it produces.
Tests for the cyclisation of muconolactones into their dilactones demonstrated that 
like optically active 4-methylmuconolactone (22), optically active 4-ethylmuconolactone 
(76) can also cyclise non-enzymically under mild condition such as storage at room 
temperature to give the dilactone with opposite optical rotation. Whereas racemic 3,4-
6 8
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dimethylmuconolactone (80), just like 3-methylmuconolactone (23), does not cyclise 
even under very vigorous conditions such as strong acid and heating.
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C H A PT E R
____________________________________________THREE
EXPERIM ENTAL
M.p.s were recorded on a Kofler hot-stage apparatus and are uncorrected. I.R. 
spectra were recorded on a Perkin-Elmer 580 or 257 spectrometer by Mr. G. McCulloch. 
lH NMR spectra were recorded on a Perkin-Elmer R34 (90 MHz) spectrometer, unless 
otherwise stated. 200 MHz spectra were recorded by Mr. J. Gall on a Bruker W.P. 200 
SY instrument in the pulsed Fourier Transform (F.T.) mode. Deuteriochloroform was 
used as the solvent with tetramethylsilane as internal standard unless otherwise stated. All 
proton chemical shifts are quoted to the nearest 0.01 ppm. Low resolution mass spectra 
were recorded by Mr. A. Ritchie and his staff in the E.I. mode at 70 eV on an 
A.E.I.M.S. 12 instrument, and high resolution spectra on an A.E.I.M.S. 9 instrument 
coupled to a GEC-905 computer for data collection and processing. Microanalysis was 
performed by Mrs. K. Wilson. Microbiological tests were done by Mrs P.Tait and her 
colleagues. Analytical TLC was carried out on precoated Merck Kieselged GF254 plates 
of thickness 0.25 mm. Spots were viewed under a UV lamp (254 mm) and developed by 
iodine vapour. Column chromatography was carried out on Merck silica HF254 
according to the method of Harwood(Ref. 82). Preparative TLC was carried out on 20 
cm x 20 cm glassplates coated with a 0.75 mm layer of Merck GF254 silica with 
detection of compounds by UV light.
"Ether" refers to diethyl ether throughout. Solutions in organic solvents were 
dried, unless otherwise stated, over anhydrous sodium sulphate and evaporated in a 
Buchi Rotavapor.
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3.1 C H EM IC A L SYNTHESIS
3.1.1 Fully D euteriated  Pyrocatechol
Fresh deuterium chloride solution was prepared as reported by Thomas et 
a/.(Ref.59). Into a 25 ml two-neck, round-bottomed flask was put deuterium oxide (10 
ml). The system was cooled with ice, and freshly distilled thionyl chloride (2.62 g , 41 
mmol) was added dropwise with stirring. The sulphur dioxide that formed was bubbled 
away by dry nitrogen. The pyrocatechol (1.10 g, 10 mmol) was then added and the 
mixture was kept heating at 90 °C overnight. The solvent was evaporated, and a white 
solid (1.0 g , 91%) was left, m.p. 103-103 °C. There was no signal on the NMR 
spectrum by comparision of it with the spectrum obtained from an equal amount of 
pyrocatechol, indicating the completion of the deuteriation reaction.
3.1.2 3-, 5-, 6-D euteriated  Pyrocatechols
(1) 4 -M e th v l-I3 -2H l pyrocatechol (63)
6-Brom oisovaniIlin (84). -To a solution of isovanillin (83) (10 g, 65 mmol) in 
acetic acid (60 ml) was added bromine (10.7 g, 67 mmol) in acetic acid (15 ml) gradually 
with stirring at room temperature during ca. 1.5 h. After another 2 h, the precipitated 
white crystals were filtered off. The filtrate was evaporated to half the volume to produce 
a further crop of crystals and finally to dryness to give a dark brown oil, which then 
solidified. Recrystallisation of the combined first and second crops gave 2-bromo- 
isovanillin as white crystals (5.0 g, 33%), m.p. 210-212 °C (from ethanol) (lit., 211- 
212°C) (Ref. 61). The mother liquors were evaporated to dryness and combined with the 
brown solid. Recrystallisation of this brown mass from ethanol-water three times, to
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constant melting point, gave 6-bromoisovanillin (84) as its monohydrate (6.9 g, 46%), 
m.p. 109-110 °C (from ethanol-water) (lit., 111-112 °C) (Ref. 61).
6-B rom o-[2-^H ]isovanillin (85).- 6-Bromoisovanillin (84) monohydrate (1.14 g,
4.6 mmol), deuterium oxide (2.2 ml), and triethylamine (473 mg,4.6 mmol) were mixed 
and heated under reflux under nitrogen for 36 h. The reaction mixture was allowed to 
cool and was acidified with 6 N hydrochloric acid using Congo Red indicator (blue 
colour). The mixture was extracted with ether (3 x 50 ml). The ether extract was washed
9
with water and dried. Evaporation of the ether gave 6-brom o-[2-H]-isovanillin (85) 
(0.79 g, 75%), m.p. 109-111 °C (lit., 109-112 °C). The *H NMR spectrum  
[(CD3)2SO] showed a singlet at 8 7.30 (1 H, 5-H) and no significant signal at 5 7.35 
for 2-H.
6-B rom o-[2-^H ]protocatechuic aldehyde (86).- Anhydrous aluminium chloride 
(1.91 g, 15 mmol) was suspended in a solution of 6-bromo-[2- H] isovanillin (85) 
(3.0g, 13 mmol) in dichloromethane (20 ml). Pyridine (4.53 g, 57 mmol) was added 
slowly to this ice-cooled, stirred mixture under a nitrogen atmosphere. The resulting 
clear, light-orange solution was heated under reflux for 24 h under nitrogen. The 
darkened solution was cooled and acidified with 6 N hydrochloric acid until a Congo Red 
indicator became blue. The lower dichloromethane layer was discarded (it mainly 
contained unreacted starting material) and the aqueous layer was extracted with ether. The 
extracts were washed with water and then dried and evaporated to give the product (86) 
as a yellowish solid (2.3 g, 89%), m.p. 220-224 °C (from ethanol-water) (lit., 220 °C) 
(Ref. 62). The 1 H NMR spectrum [(CD3) 2SO] showed the disappearance of the singlet 
at 8 2.92 (OMe) present in the starting material. There was no indication of loss of 
deuterium, 8 7.25 (1 H, s, 2-H).
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[2-^H]Protocatechuic aldehyde (87). - Triethylamine (101 mg, 1 mmol) and 10% 
palladium-carbon (38 mg) were added to a solution of 6-Bromo-[2-^H]protocatechuic 
aldehyde (86) (216 mg, lmmol) in methanol (350 ml). The mixture was hydrogenated 
with stirring at room until ca. 1 equivalent of hydrogen (25 ml) was absorbed. The 
mixture was filtered and the filtrate was evaporated . The residual brown solid was 
extracted with ether. Evaporation of the ether gave the product (87) as a yellowish solid 
(120 mg, 87%). The NMR spectrum [(CD3)2SO] showed signals at 8 6.90 and 6 
7.30 (2 H, ABq, J  9Hz, 5-and 6-H). There was no significant signal at 6 7.25 for 2-H.
4-M ethyl-[3-^H] pyrocatechol (63). - [2-^HJProtocatechuic aldehyde (87) (290 
mg, 2 mmol) in ethanol containing a catalytic amount of 1 M hydrochloric acid in ethanol 
(0.04 ml,c a . 0.04 mmol) was hydrogenated over 10% palladium carbon (74 mg) with 
stirring at room temperature for 1 h until sufficient hydrogen (100 ml, 4.2 mmol) was 
absorbed. The mixture was filtered and the filtrate was neutralised with solid sodium 
bicarbonate. Ethanol was evaporated under reduced pressure and the residue was 
extracted with ether, leaving a mass of inorganic salts. Evaporation of the ether gave the 
product (63) as a brown oil (0.196 g, 77%) ; 8 [D2O (BulOH as standard, 8 1.22)]
2.18 (3 H, s, Me) and 6.60 and 6.85 (2 H, ABq, J  9Hz, 5- and 6- H). There was no 
significant signal at 8 6.75 arising from a proton at C-(3).
(2) 4-M ethvl-r5-2Hlpvrocatechol (96)
Acetyl vanillin (91). - (a) Acetic anhydride (10.1 ml ,ca. 11.1 g, 0.1 mol) in ether 
(100 ml) was added slowly with stirring at room temperature to a solution of vanillin (90) 
(15.4 g, 0.1 mol) and sodium hydroxide (4.0 g, 0.1 mol) in water (80 ml). The mixture 
was stirred for 30 min and the organic phase was separated, washed with water and 
dried. Evaporation of the ether gave white crystals of acetylvanillin (91) (17 g, 82%)
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(lit., 81%) (Ref. 64). Recrystallisation gave white needles, m.p. 76-77 °C (from ethanol) 
(lit., 76-77 °C) (Ref.64). (b) A mixture of vanillin (90) (25 g, 0.18 mol), acetic acid (25 
ml), and analytical grade pyridine (5 ml) was heated under reflux for 3 h. The reaction 
mixture was cooled and concentrated under reduced pressure. The residual oil solidified 
on cooling. Recrystallisation gave white crystals (28 g, 89%) (lit., 81.7%), m.p. 76-77 
°C (from ether) Git., 76-77 °C) (Ref. 64).
6-B rom ovanillin  (92). - A mixture of acetylvanillin (91) (38.8 g, 0.2 mol), 
anhydrous sodium acetate (38.8 g, 0.47 mol), iodine (0.25 g, 1 mmol), acetic acid (150 
ml), and bromine (11 ml, ca. 44 g , 0.27 mol) was heated with stirring at 45 °C for 3 h. 
The warm reaction mixture was poured slowly into cold water (2 L) with vigorous 
stirring. A light orange solid precipitated after 2 h. The precipitate was collected by 
filtration and washed thoroughly with water and dried under vacuum. 6-Bromo-O- 
acetylvanillin, so obtained (45 g, 83%) was used without purification. The bromoacetyl 
compound (45 g, 0.165 mol) was dissolved in water (150 ml) containing potassium 
hydroxide (45 g, 0.8 mol) and heated at 80 °C for 1 h with stirring. The clear brown 
liquid was cooled in ice and acidified with concentrated hydrochloric acid to pH 3-4. The 
resulting pale-brown precipitate was collected by filtration, washed thoroughly with cold 
water, and dried under vacuum. Treatment of this solid with charcoal in ethanol gave 6- 
bromovanillin (92) as white crystals (28 g, 73% ), m.p. 176-177 °C (from ethanol) (lit., 
176-177 °C) (Ref. 64).
6-Bromovanillin dimethyl acetal (93). - 6-Bromovanillin (92) (2.2 g, 96 mmol), 
dried and distilled methanol (50 ml), trimethyl orthoformate (2.2 g, 21 mmol), and 
ammonium nitrate (750 mg, 9.4 mmol) were heated under reflux under a dried nitrogen 
atmosphere overnight (20 h). The reaction mixture was slightly cooled and evaporated 
under reduced pressure. The residual oil was dissolved in anhydrous ether and passed
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through Celite which was then washed thoroughly with ether. Evaporation of the ether 
solution gave a light coloured oil, which was allowed to stand under high vacuum to yield 
a white solid (2.3 g , 88%). Recrystallisation from light petroleum (b.p. 60-80 °C) gave 
the acetal (93), m.p. 42-43 °C.
[6-2H]Vanillin (94). - 6-Bromovanillin dimethyl acetal (93) (625 mg, 2.3 mmol), in 
anhydrous ether (10 ml) (dried over sodium hydride) was cooled with solid carbon 
dioxide-acetone to -50 °C and stirred under dry nitrogen. Butyl-lithium in hexane (1.6 
M, 8 ml, 12.8 mmol) was added over a period of 10 min. The solution was allowed to 
warm to room temperature. Deuterium oxide (98%, 0.3 ml, 15 mmol) was added slowly 
over 2 h. The mixture was refluxed gently for 1 h, water (5 ml) was added, and the 
aqueous layer was adjusted to pH 3-4 with concentrated hydrochloric acid. The mixture 
was refluxed for another 10 min. The ether-hexane layer was separated and the aqueous 
layer was saturated with sodium chloride and then extracted with ether. The combined 
ether solutions were treated with charcoal and dried. Evaporation of the ether gave a dark 
oil, which was separated by chromatography on a short GF254 silica column. Elution 
with chloroform gave [6-2H] vanillin (94) as a white solid (56 mg, 17%); 6 3.92 (3 H, s, 
4-OMe), 6.78 (1 H, br s, 5-H) , 7.26 (1 H, s, 2-H) and 9.18 (1 H, s, CHO). There is 
also a weak peak at 8 7.38 for 6-H, which indicated incomplete deuteriation.
[6-2H]Protocatechuic aldehyde (95). - [6-2H]Protocatechuic aldehyde (95), m.p. 
154-156 °C (lit., 153-154 °C) (Ref. 60), was obtained (83%) by demethylation of [6- 
2H]vanillin (94) under the conditions described for demethylation of (85). The *H NMR 
spectrum confirmed that demethylation had occurred without loss of deuterium.
The compound (95) was also prepared from 6-bromoprotocatechuic aldehyde 
(97) in good yield (99%) and purity by reduction in tetrahydrofuran by deuterium gas 
(see Fig.l). Deuterium gas was prepared by adding deuterium oxide slowly to sliced
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clean lithium with vigorous stirring, and then was passed through a trap cooled with solid 
carbon dioxide-acetone to get rid of moisture. A mixture of 6-bromoprotocatechuic 
aldehyde (97) (1.10 g, 5 mmol), 10% palladium-carbon (190 mg), triethylamine (505 
mg, 5 mmol), dry tetrahydrofuran (69 ml) and deuterium oxide (0.69 ml, 1% v/v of 
THF) was debrominated with stirring at room temperature until 1 equivalent of newly- 
prepared deuterium gas was absorbed. The reaction mixture was worked up as usual. A 
yellowish solid was obtained (0.7 g, 99.7%); 8 [(CD3)2SO] 6.95 (1 H, s, 2-H), 7.25 
(1 H, s, 5-H), and 9.65 (1 H, s, CHO). there was no signal at about 8 7.35 arising 
from a proton at C-(6).
vaccum
OUTLET
F ig .l. Apparatus Skeleton for Deuterium Debromination
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6-Bromoprotocatechuic aldehyde (97). - 6-Bromoprotocatechuic aldehyde (97), 
m.p. 222-224 °C (lit., 220 °C) (Ref. 62) was obtained via demethylation of 6- 
bromovanillin (92) by anhydrous aluminium chloride and pyridine according to the 
procedure for the preparation of compound (86).
4-Methyl-[5-2H]pyrocatechol (96). - This compound (96) was prepared from [6- 
2H]protocatechuic aldehyde (95) (86%) in a similar way to the preparation of compound 
(63); 8 [D2O (BulOH as standard, 8 1.22)] 2.25 (3 H, s, 4-CH3), 6.70 (1 H, s, 3-H), 
and 6.75 (1 H, s, 6-H).
(3) 4-M ethvl-r6-2 Hlpvrocatechol (64)
Pyrocatechol monobenzyl ether (101). - Sodium ethoxide, prepared from sodium 
(18.4 g, 0.8 mol), in dry ethanol (280 ml) was added dropwise with stirring to 
pyrocatechol (1) (8 g, 0.8 mol) in ethanol (280 ml) under nitrogen at room temperature. 
Benzyl chloride (102 g, 0.806 mol) was added slowly to the dark orange solution, which 
was then stirred for a further period of 30 min. The mixture was heated under reflux for 2 
h to complete the reaction. The solution was allowed to cool and was acidified with 5 N 
hydrochloric acid. The precipitated sodium chloride was filtered off and the filtrate was 
kept in the refrigerator overnight to allow the dibenzyl ether to precipitate. This was then 
filtered off. The filtrate was evaporated and the residue was extracted with ether. The 
ether was evaporated under reduced pressure and fractional distillation of the residue gave 
the monobenzyl ether (101) as a pale yellow liquid (87 g, 54%), b.p. 158 °C (2-3 
mmHg) [lit., 173 °C (13 mmHg)] (Ref.69).
3 - 0 -Benzylprotocatechuic aldehyde (98). - Sodium hydroxide (39.9 g, 0.99 
mol) in water (42 ml) was added to the pyrocatechol monobenzyl ether (101) (10.5 g,
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0.053 mol) in ethanol (88 ml) with stirring at room temperature. Then chloroform (31.5 
g, 0.26 mol) was added slowly with stirring to the mixture. The mixture was stirred for 
1.5 h and then heated under reflux for 30 min. Solvent were evaporated and the residue 
was acidified with 5 N hydrochloric acid. The dark brown oil which formed was 
extracted with ether (3 x 250 ml). The combined ether extracts were washed with water, 
dried and evaporated. The residual dark oil was chromatographed on a silica gel, GF 254 
column. Elution with benzene gave the O-benzylpyrocatechol (101) and elution with 
benzene-chloroform (1:1) gave the 3-O-benzylprotocatechuic aldehyde (98) (2.3 g, 
19%), m.p. 112-113 °C (from benzene) (lit., 113-114°C) (Ref. 70).
3-O -Benzyl-[5-2 H]protocatechuic aldehyde (99). - The compound (99), m.p. 
110-113 °C (lit., 112-114 °C) (Ref. 60), was obtained (87%) from (98) by exchange in 
deuterium oxide and triethylamine as described before (Ref. 62).
[5-2H]Vanillin (102). - [5-2H]Vanillin (102), m.p. 77-79 °C (from water) (lit., 79- 
81 °C) (Ref. ), was obtained from vanillin (90) by deuterium oxide/triethylamine as 
described before (Ref. 62).
[5-2H]Protocatechuic aldehyde (103). - This compound (103), m.p. 153-156 °C 
(lit., 153-154 °C) (Ref. 60), was prepared from its O-methyl ether, [5-2H]vanillin (102) 
(82%) by following the procedure described before (Ref. 62).
4-M ethyl-[6-2H] pyrocatechol (64). - The compound (64) was prepared from 3-
0-benzyl-[5-2H]protocatechuic aldehyde (99) (81%) and from [5-2H]protocatechuic 
aldehyde (103) (88%) by hydrogenolysis as described in the preparation of compound 
(63), 8 [D2O (Bu*OH as standard, 8 1.22)] 2.15 (3 H, s, 4-Me), 6.65 (1 H, s, 6-H), 
and 6.75 (1 H, s, 2-H).
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3.1.3 4-E thyIpyrocatechoI (81)
4 -B enzoyloxy-3-hydroxyethyIbenzene (105). - A mixture of 4-ethylphenol 
(104) (6.1 g, 0.05 mol), benzoyl peroxide (12.11 g, 0.05 mol) and dried chloroform 
(50 ml) was heated to reflux for 6 h. After being cooled, the resultant brown solution was 
washed with saturated aqueous sodium bicarbonate until alkaline pH indicated that all the 
benzoic acid that had formed had been removed. The chloroform layer was dried and 
evaporated to dryness under reduced pressure. The residual oil was scratched under 
hexane. The resulting orange coloured solid was collected and recrystallised from 
chloroform-hexane to give the cream coloured benzoyl ester (4.5 g, 37%), 4- 
benzoxyloxy-3-hydroxy-ethylnenzene, m.p. 126-128 °C (Found: C, 74.21; H, 5.76%. 
C 15H 14O3 requires C, 74.36; H, 5.82%); 6 1.10 (3 H, t, J  7Hz, 4-CH2-CH3), 2.56 (2 
H, q, J  7Hz, CH2-CH3), 6.68-8.30 (9 H, m, Ar-H and -OH, 1 H exch. with D2O).
4-EthyIpyrocatechoI (81). - The ester (2.2 g, 10 mmol) was added slowly with 
stirring to dilute aqueous sodium hydroxide solution (100 ml) containing sodium 
hydroxide (0.8 g, 20 mmol) under nitrogen. The solution, which became dark in colour, 
was stirred overnight and then acidified with concentrated hydrochloric acid, and 
saturated with sodium chloride. The ethylpyrocatechol (81) that had formed was 
extracted with ether and the combined ether extracts were washed with saturated sodium 
bicarbonate to remove benzoic acid and then water. The dark ether solution was dried and 
evaporated. The residual dark mass was distilled (Kugelrohr distillation) and a clear pale 
yellow liquid was obtained which then solidified (0.95 g, 76%), b.p. 125 °C (13 mmHg) 
[lit., 172 -175 °C (35 mmHg)]. m.p. 36-38 °C (lit., 39 °C) (Ref. 75). 5 1.12 (3 H, t, J  
7Hz, 4-CH2-CH3), 2.52 (2 H, q, J  7Hz, 4-CH2-CH3), 6.54-6.84 (3 H, m, Ar-H).
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3.1.4 4,5-Dimethylpyrocatechol (82)
Potassium nitrosodisulfonate (Fremy's salt) (118). - The procedure given by 
Singh (Ref. 74) was followed with minor changes. In a 5 L three neck-round-bottomed 
flask were placed distilled water (1 litre) and crushed ice (500 g), sodium bicarbonate 
(79.2 g, 0.94 mol), sodium nitrite (66 g, 0.84 mol). The mixture was thoroughly mixed 
with a mechanical stirrer and was externally cooled to - 5 °C by a mixture of salt and ice. 
Sulphur dioxide was then passed into the mixture rapidly, and its temperature was 
controlled at - 5 °C to - 2 °C. When the colour changed to orange-brown (approx. 50 min 
), the passage of sulphur dioxide was immediately stopped. The mixture was stirred for 
an additional 10 min., during which time it became colourless. Clean nitrogen was then 
bubbled through the solution for 5 min. and the pH of the solution was adjusted to 10.1 
with 18% ammonium hydroxide (50 ml). The solution was stirred at - 2 °C for 30 min, 
and IN  potassium permanganate (120 g in 760 ml water), cooled to - 3 °C, was then 
added portion-wise at a rate which kept the temperature below 5 °C. The mixture was 
stirred for 1 h and then allowed to stand at the same temperature for 1 h. The dark-brown 
slurry was filtered through a Celite bed into a saturated solution of potassium chloride 
(500 g in 140 ml water at 30 °C). On cooling, the solution yielded an orange crystalline 
precipitate which was collected by Buchner funnel, washed with saturated potassium 
chloride and ammonial methanol (containing about 10% concentrated ammonia), dried 
under vacuum over calcium oxide, in the presence of ammonium carbonate in a separate 
dish to provide an ammonia atmosphere, and the product (118) (170 g, 72%) stored in a 
refrigerator.
4,5-Dim ethyl-l,2-benzoquinone (117).- Sodium dihydrogen phosphate (1.88 g) 
was dissolved in water (525 ml) in a 1 L conical flask, with stirring. To this solution was 
added potassium nitrosodisulfonate (Fremy's salt) (12 g, 41 mmol). The mixture was
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stirred to give a clear, purple solution. A solution of 3,4-dime thy lphenol (116) (2.0 g, 
16.3 mmol) in ether (44 ml) was added quickly to this purple solution. The mixture was 
stirred for another 20 min. The colour of the solution changed to red-brown. The o- 
quinone thus formed was subsequently extracted three times with chloroform (total 130 
ml). The combined extracts were dried and evaporated under reduced pressure at room 
temperature. The residual, oily, red-brown crystals were slurried with ice-cold ether (2 
ml). The resulting dark-red crystals (1.2 g, 51%) had m.p. 99-101 °C (lit., 102 °C) 
(Ref.78); 8 2.15 (6 H, s, 4- and 5- Me) and 6.21 (2 H, br s, 3- and 6-H).
4,5-Dimethylpyrocatechol (82). - This compound was prepared by reference of 
Stubeurauch and Knuppen's work. 4,5-Dimethyl-1,2-benzoquinone (117) (1.2 g, 8.8 
mmol) was dissolved in chloroform (120 ml) in a separating funnel. Potassium iodide 
(4.0 g, 24 mmol) in acetic acid (250 ml) was added to this dark red solution, and the 
mixture was shaken for 2 min. Iodine was removed by washing with 5% sodium 
thiosulphate solution and then water. The organic layer was dried and evaporated. The 
residual oil was distilled (Kugelrohr distillation) to give white solid (750 mg, 63 %), 
m.p. 84-86 °C; 8 2.10 (6 H, s, 4- and 5-M e), 6.65 (2 H, s, 3- and 6-H) and 5.70 (2 H, 
br s, 1- and 2-OH, exch. with D2O).
3.1.5 M onolactones
2-Bromobutan-4-olide (125). - A mixture of freshly distilled butan-4-olide (124) 
(17.2 g, 0.2 mol) and phosphorus tribromide (0.2 ml) was heated to 100 °C under 
nitrogen. Bromine (28 g, 0.18 mol) was added to it slowly over a peroid of 5 h at a rate 
which kept the temperature between 100 °C-130 °C. The reaction mixture was kept at 
130 °C overnight. The mixture was allowed to cool and nitrogen was bubbled through it 
for 1 h. After three-round fractional distillations, pure 2-bromobutan-4-olide (125) was
81
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obtained, b.p. 76 °C (0.5 mmHg) [lit., 125 °C (12 mmHg)] (Ref. 85); 5 2.34-3.16 (2 
H, m, 3-H), 4.36-4.78 (3 H, m, 2-H and 4-CH2).
2, 2-Dibromobutan-4-olide (70). - A mixture of freshly distilled butan-4-olide 
(124) (17.2 g, 0.2 mol) and phosphorus tribromide (0.2 ml) was heated to 170 °C under 
nitrogen. Bromine (96 g, 0.6 mol) was added slowly to it at a rate which kept at a 
temperature < 190 °C. The resultant mixture was kept at about 190 °C overnight. The 
work-up of the product was the same as that described in the preparation of 2- 
bromobutan-4-olide (125). The colourless liquid, 2, 2-dibromobutan-4-olide (70), b.p. 
65 °C (O.lmmHg) [lit., b.p. 115 °C (8mmHg)] (Ref. 85) was collected and the liquid 
crytallized on standing, m.p. 47-48 °C; 8 3.25 (2 H, t, /  7 Hz, 3-CH2), 4.44 (2 H, t, J  
1 Hz, 4-CH2).
3.1.6 Dimethylmuconolactones
3,4-Dim ethyl-6-nitrophenol (123). - 3,4-Dimethylphenol (116) (6.0 g, 0.049 
mol) in acetic acid (60 ml) was added rapidly to concentrated nitric acid (9 ml, d 1.42, 
0.202 mol) in acetic acid (30 ml), which was cooled using a mixture of ice and salt. The 
resultant mixture was diluted at once with water and the oily precipitate was scratched to 
induce crystallisation. The dark orange solid was collected and washed thoroughly with 
water. 3,4-Dimethyl-6-nitrophenol (123) (2.4 g, 29%) was separated from the solid 
mixture, which contained approx. 40 % 2, 6-dinitro compound by chromatography on a 
column of silica gel HF254, which was eluted with chloroform-hexane (3:7, v/v). The 
product had m.p. 84-86 °C (lit., 87 °C) (Ref. 83); 6 2.20 (3 H, s, Me), 2.25 (3 H, s, 
Me), 6.70 (1 H, s, 2-H) and 7.70 (1 H, s, 5-H).
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3.4-D im ethyIm uconolactone (77). - 3,4-D im ethyl-6-nitrophenol (123) (4.0 g, 
0.024 mol) was added in portions to concentrated sulphuric acid (15 ml) at 110-115 °C 
during the course of 2 h with stirring. After another 30 min stirring, the black mixture 
was allowed to cool to room temperature and was carefully poured onto crushed ice. 
When the ice had melted, the aqueous solution was saturated with sodium chloride and 
extracted continuously with ether for 48 h. The ethereal extract was dried and evaporated 
to give a yellowish solid, which was recrystallised from benzene giving white crystals of
3.4-dimethylmuconolactone (77) (1.6 g, 48.5%), m.p. 103-104 °C (lit., 103-104 °C) 
(Ref. 81); 8 [200MHz] 1.54 (3 H, s, 4-Me), 2.08 (3 H, s, 3-Me), 2.71 and 2.92 (2 H, 
ABq, J  8Hz, 5-CH2), 5.78 (1 H, s, 2-H) and 8.70 (1 H, br s, COOH, exch. with 
D20).
2-B rom o-3,4-dim ethylm uconolactone (78). - The title compound (78) (79%) 
was prepared from (±)-l,5-dimethyl-8-bromodilactone (72). The bromodilactone (72) 
(125 mg, 0.5 mmol) was dissolved in dichloromethane (2 ml) containing triethylamine 
(50.5 mg, 0.5 mmol) and the solution was stirred at room temperature for 1 h. The 
disappearance of bromodilactone (72) was followed by TLC. The evaporation of 
dichloromethane gave the 2-bromo-3,4-dimethylmuconolactone triethylamine salt. The 
salt was dissolved in methanol and stirred with acid resin, Ambulite 200, for 30 min. and 
the resin was filtered off and washed thoroughly with methanol. The combined methanol 
solution was evaporated and the free acid of 2-bromo-3,4-dimethylmuconolactone (78), 
2-bromo-3A-dimethyl-4-carboxylmethyl-Aa -butenolide, was given. The product had 
m.p. 103-105 °C (chloroform-hexane); (Found: C, 38.40; H, 3.64%. CgH 9BrC>4 
requires C, 38.58; H, 3.64%); flmax 1790 and 1650 cnr^-CO-); 5 (CD3OD) 1.58 (3 
H, s, 4-Me), 2.15 (3 H, s, 3-Me), and 2.94 (2 H, s, 5-CH2); m/e, 250 and 248 (1:1)
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3.1.7 D ilactones
(1) T he m uconodilactones
(±)-4-Brom om uconodilactone (127).- (±)-Muconolactone (8) (142 mg, 1 mmol), 
prepared by Dr. G.V. Rao was dissolved in aqueous sodium hydrogen carbonate (84 mg 
in 3 ml water). Bromine (160 mg, 1 mmol) in dichloromethane (5 ml) was added at 0 °C 
with stirring. The mixture was allowed to warm to room temperature and was stirred for 
7 h to complete the reaction. Aqueous sodium thiosulphate was added to remove any 
traces of bromine. The mixture was extracted with dichloromethane (3 x 10 ml) and the 
extracts were dried (MgSC>4). Evaporation of the solvents gave the bromodilactone (127) 
as a white solid, which recrystallised from chloroform-hexane as white crystals (200 mg, 
90.5%). (±)-4-Bromo-dilactone (127) had m.p. 137-139 °C; 8 2.98 (2 H, dd, J  4 and 2 
Hz, 8-H2), 4.46 (1 H, d, J  1 Hz, 4-H), 5.12 (1 H, dd, J  4 and 1 Hz, 5-H), 5.42 (1 H,
br s, 1-H).
(±)-4,4-D ibrom om uconodilactone (73). - The 4-bromomuconodilactone (127) 
(110 mg, 0.5 mmol) was dissolved in water containing sodium bicarbonate (42 mg, 0.5 
mmol) and the mixture was stirred for 1.5 h to get a clear solution. To this, bromine (80 
mg, 0.5 mmol) in dichloromethane (3 ml) was added and left stirring for another 3 h. The 
dichloromethane layer was separated and the aqueous solution was extracted with 
dichloromethane. The combined organic layers were washed with saturated sodium 
bicarbonate and water, and then dried. Evaporation of the solvent gave 4,4-dibromo-3,l- 
dioxo-2y6-dioxabicyclo-(3, 3, 0)-octane (73) as a white solid. Recrystallisation from 
ethyl acetate-hexane gave rods (135 mg, 90%), m.p. 128.5-130 °C (Found: C, 24.21; H, 
1.26%. C6H4Br204  requires C, 24.03; H, 1.34%); Omax(CHCl3) 1807cm-1 (-CO-); 8 
3.10 (2 H, d with fine splitting, 8-CH2), 5.28 (1 H, d, J  4Hz, 5-H), 5.46 (1 H, br m, 1-
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H); m /e  301.8429 (0.2%), 299.8482 (0.3%), and 297.8507 (0.2%). C6H481Br20 4? 
C6H481Br79Br0 4? and C6H479Br20 4 reqUire 301.8420, 299.8507, and 297.8537.
(±)-M uconodilactone (59). - To a suspension of the bromodilactone (127) (110 
mg, 0.5 mmol) in dry benzene (2 ml) azoisobutyronitrile (7 mg, 10% mmol of dilactone) 
was added under nitrogen and the flask was sealed with a subaseal. Tributyltin hydride 
(0.27 ml, ca, 0.6 mmol) was injected into this mixture, which was then warmed to 30-40 
°C to get clear solution. The white solid was precipitated 5 min. later and the mixture was 
heated for another 15 min. and then allowed to cool to room temperature with a further 1 
h stirring. The solvent was evaporated and The residue was triturated with hexane. The 
white solid was collected and recrystallised from chloroform-hexane as a white solid (65 
mg, 92%), m.p. 131-133 °C (lit., 129-130 °C) (Ref. 12); 6 2.98 (4 H, d, 4- and 8-H), 
5.20 (2 H, br s, 1- and 5-H). This compound had been fully characterised by Dr. G. V. 
Rao.
(2) M ethvl-substituted muconodilactones
(±)-l-M ethyl-8-bromomuconodi!actone (37). - This compound (37) (89%) was 
prepared from (±)-3-methylmuconolactone (35) supplied by Dr. G. V. Rao following the 
same methods used for the parent bromomuconodilactone (127). It had m.p. 88-89 °C, 
6 1.76 (3 H, s, 1-Me), 2.94 (2 H, m, 4-H), 4.45 (1 H, s, 8-H), and 4.96 (1 H, m, 5- 
H). The m.p. and spectrum agreed with those obtained by Dr. G. V. Rao.
(±)-l-M ethyl-8,8-dibromodilactone (60). - (± )-l-M ethy l-8 ,8-dibrom odilactone 
(60) (93%) was prepared from (±)-l-methyl-8-bromomuconodilactone (37) following 
the procedure described for the parent dibromomuconodilactone (73). The dilactone (60) 
had m.p. 153-155 °C (from ethyl acetate-hexane); 8 (200MHz) 1.87 (3 H, s, 1-Me),
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2.75-3.20 (2 H, AB part of ABX, J  18.6 Hz, 3.7Hz and 1.1Hz, 4-H2), and 5.10 (1 H, 
X part of ABX, J  3.7 Hz and 1.1Hz, 5-H). This compound had been fully characterised 
by Dr. G. V. Rao.
(±)-l-M ethylimiconodilactone (38). - The (±)-l-methyldilactone (38) (91%) was 
obtained via denomination of (±)-l-methyl-8-bromomuconodilactone (37) by tributyltin 
hydride and AIBN in benzene following the procedure used in the preparation of parent 
dilactone (59). The dilactone had m.p. 90-91 °C (from chloroform-hexane); 8 (D6- 
acetone) 1.65 (3 H, s, 1-Me), 2.55-3.45 (4 H, m, 4- and 8-CH2), and 5.15 (1 H, m, 5-
H). The m.p. and spectrum agreed with those obtained by Dr. G. V. Rao.
l-m eth y l-4 -b r o m o -[8 -2H]-iiiuconodilactone (130). - The crude (4S ,5S)-4- 
methyl-[5-2H]muconolactone (65) (20mg, 0.13 mmol), obtained by feeding [3-2H]-4- 
methylpyrocatechol (63) to P. putida, was dissolved in a solution of sodium hydrogen 
carbonate (11.0 mg, 0.13 mmol) in water (0.25 ml). Bromine (22.0 mg, 0.13 mmol) in 
dichloromethane (0.4 ml) was added at 0 °C with stirring. The mixture was allowed to 
warm to room temperature and was stirred for 7 h to complete the reaction. Aqueous 
sodium thiosulphate was added to remove any traces of bromine. The mixture was 
extracted with dichloromethane (3x10ml) and the extracts were dried (MgSC>4 ). 
Evaporation of the solution gave the bromodilactone (130), 4-brom o-\-m ethyl-3J-  
dioxo-2,6-dioxabicyclo-(3, 3, 0)-octane (130), as an orange coloured solid (20 mg); 8 
[(CD3)2CO] 1. 89 (3 H, s, 1-CH3), 3.05 (1 H, br s, 8-CH), 4.82 (1 H, s, 4-H) and
5.22 (1 H, s, 5-H). The procedure was that carried out by Dr. G. V. Rao with the 
unlabelled material.
1-M ethyl-[8-2H]-muconodilactone (67). - Azoisobutyronitrile (AIBN) (1.2 mg, 
0.0086 mmol) was added under dry nitrogen to a suspension of the bromo-
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muconodilactone (130) (20 mg, 0.086 mmol) in dry benzene (0.18 ml) and the flask was 
sealed with a subaseal. Tributyltin hydride (0.03 ml, ca. 0.011 mmol) was injected into 
this mixture, which was then warmed to 30-40 °C. The solution was stirred for 1 h and 
evaporated. The residue was triturated with hexane and the residue solid was 
recrystallised from chlorofom-hexane to yield the dilactone (67), %-deuterio-\-methyl- 
3J-dioxo-2,6-dioxabicyclo-(3, 3, 0)-octane (67), as white solid (2 mg), m.p. 107-108 
°C; 5 1.70 (3 H, s, Me), 2.65 and 3.45 (3 H, m, 4-H2 and 8-H ), and 5.20 (1 H, br s,
5-H).
(3) Ethvl-substituted M uconodilactones
(±)-l-Ethyl-8-brom om uconodilactone (71). - The title compound (71) (88%) 
was prepared from (±)-l-ethylmuconolactone (126) supplied by Dr. D.R.Jaap following 
the procedure described in the preparation of the parent bromodilactone (127), 4-bromo- 
\-e thy l-3 ,l-d ioxo-2 ,6 -d ioxab icyclo -(2>, 3, 0)-octane  (71) had m.p. 101-102 °C 
(chloroform-hexane) (Found: C, 38.79; H, 3.64%. CgHqBrC^ requires C, 38.58; H,
3.64%); 8 1.10 (3 H, t, I-CH2-CH3), 1.53-2.40 (2 H, q with fine splitting, 1-CH2- 
CH3), 2.98 (2 H, m, 4-H2), 4.45 (1 H, s, 8-H), and 4.96 (1 H, m, 5-H).
(±)-l-Ethyldi!actone (79).- The (±)-l-ethyldilactone (79) (89%) was prepared from 
the bromodilactone (71) by denomination following the same procedure as the parent 
dilactone. \-Ethyl-3J-dioxo-2,6-dioxabicyclo-(3, 3, 0)-octane (79) had m.p. 121-123 
°C (chloroform-hexane) (Found (%), C, 56.19; H, 6.08; C g H jo 0 4  requires (%), C, 
56.46; H, 5.92); 8 1.10 (3 H, t, J  7 Hz, I-CH2-CH3), 1.86 (2 H, q J  1 Hz, 1-CH2- 
CH3), 2.65-3.05 (4 H, m, 4- and 8-CH2), and 4.85 (1 H, t, 5-H).
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(-)-l-E thyl-4-brom om uconodilactone (131). - (-)-l-E thyl-4-brom odilactone 
(131) was prepared from optically active (+)-4-ethylmuconolactone (76) obtained by 
feeding 4-ethylpyrocatechol (81) to the bacteria Pseudomonas putida described in 3.2.1. 
The product bromodilactone, \-ethyl-4-bromo-3yl-dioxo-2y6-dioxabicyclo-(3y 3, 0)- 
octane (131) was semi-solid. [a ]o  - 54 0 (c 1 in methanol); 8 1.12 (3 H, t, J  7 Hz, 1-
CH2-CH 3), 1.89-2.45 (2 H, q with fine splitting, I-CH2-CH 3), 2.94 and 3.18 (2 H, 
ABq, J 19Hz, 4-CH2), 4.85 (1 H, br s, 5-H) and 5.25 (1 H, s, 8-H).
(-)-l-E thylm uconodilactone (132). - (-)-l-Ethyldilactone (132) was prepared 
from (-)-l-ethyl-4-bromodilactone (131) by the debromination in benzene with tributyltin 
hydride and AIBN. l-Ethyl-3yl-dioxo-2y6-dioxabicyclo-(3, 3, 0)-octane (132) had m.p. 
137-138.5 °C (chloroform-hexane); [a]j) - 104 0 (c 0.8 in methanol); 8 1.09 (3 H, t, J
7Hz, I-CH2-CH3), 2.85 (2 H, q, J 7Hz, 1-CH2-CH3), 2.58-3.08 (4 H, m, 4- and 8- 
CH2), and 4.85 (1 H, m, 5-H). The m.p., optical rotation and *H NMR spectrum agreed
with the corresponding dilactone obtained during storage.
(4) Dimethyl-substituted Muconodilactones
(±)-l,5-Dimethyl-4-bromom uconodilactone (72). - (±)-l,5-Dim ethyl-4-brom o- 
muconodilactone (72) (87%) was prepared from (±)-3,4-dimethylmuconolactone (77) 
following the procedure described in the preparation of the parent bromomuconodilactone 
(127). 4-brom o-ly5-dimethyl-3yl-dioxo-2y6-dioxabicyclo-(3y3y0)-octane (72) had 
m .p.l03-5°C  (chloroform-hexane); v max 1786 and 1678 cm-l (-CO-); 8 [200MHz] 
1.73 (3 H, s, 1 -M e \  1.75 (3 H, s, 5-Me) , 2.20-3.05 (2 H, m, J  18.6 and 1.1 Hz, 8- 
H2), and 4.49 (1 H, d, J 1.1Hz, 4-H); m !e 248 (0.6%) and 250 (0.6%).
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(±)-l,5-Dim ethyI-4,4-dibrom odilactone (74). - (±)-l,5-D im ethyl-4,4-dibrom o- 
muconodilactone (74) (93%) was prepared from (±)-l,5-Dimethyl-4-bromomucono- 
dilactone (72) following the procedures described for the parent dibromomucono- 
dilactone (73). Recrystallisation from chloroform-hexane gave 4,4-d ibrom o-\,5 -  
dimethyl-3,l-dioxo-2,6-dioxabicyclo-(it 3, 0)-octane (74) as neddles, m.p. 174-175 °C 
(chloroform-hexane) (Found: C, 29.31; H, 2.41%. C gH gB ^C ^ requires C, 29.30; H,
2.46%); dmax.1795 cnrl(-C O -); 8 1.89 (6 H, s, 1-Me and 5-Me), 2.78-3.08 (2 H, 
A B q,/ 18Hz, 8-H); m /<? 327.8784 (1.1%), and 325.8772 (0.5%). C g H ^ B rS lB rO /t, 
C6H479Br204  requires 327.8797, and 325.8754.
(±)-l,5-Dim ethylm uconodilactone (80). - The title compound (80) (89%) was 
prepared from (±)-l,5-dimethyl-4-bromomuconodilactone (72) via denom ination by 
AIBN and tributyltin hydride in benzene. \,5-Dimethyl-3,l-dioxo-2,6-dioxabicyclo-(3, 
3, 0yoctane  (80) had m.p. 143-145 °C (chloroform-hexane) (Found: C, 56.34; H, 
5.79%. C gH j()04 requires C, 56.46; H, 5.92%); tfmaxl786 cm "l, (-CO-); 8 2.05 (6 
H, s, 1-Me and 5-Me), 2.78-3.08 (4 H, ABq, J  18 Hz, 4- and 8-H2); m/e 170.
3.1.8 Cyclization Test of 3, 4-Dimethylmuconolactone
The cyclisation of 3,4-dimethylmuconolactone (77) was tested under various 
conditions and monitored by NMR spectrometer. The JH NMR spectrum showed that
3, 4-dimethylmuconolactone did not cyclise under these different conditions.
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Table 3. Cyclisation of dime thylmuconolactone (77)
Conditions Time (h) 1HNMR
a. dissolved in CDCI3, add 50% v/v 
CF3COOH
0.5
1
24
no change 
no change 
no change
b. refluxed in CF3COOH 24 no change
c. refluxed in 70% H2SO4 24 no change
d. stirred in 50% aqueous ethanol, 
Amberlyst-15 as catalyst
24 no change
e. dissolved in EtOAc, then absorbed 
on silica gel HF254
24
72
no change 
no change
3.1.9 The Reaction of Dibromolactones with Thiol Compounds
(1) l-M ethvl-8 .8-dibromomuconolactone with Benzvl M ercaptan
(a). Into a round-bottomed flask were put benzyl mercaptan (12.4 mg, 0.1 mmol) 
and ethanol (0.6 ml). The dibromomuconolactone (60) (15.6 mg, 0.05 mmol) was added 
to this solution and the reaction mixture was refluxed overnight. The solvents were 
evaporated and the residue was dried under high vaccum. A white solid was obtained. 
This was assumed to be a mixture of 2-bromomuconolactone (129), by comparision of 
its *H NMR spectrum with authentic sample, its ethyl ester, and disulphate (139). (b). 
The dibromodilactone (60) (25.2 mg, 0.0806 mmol) was added to a solution of benzyl 
mercaptan (9.0 mg, 0.0726 mmol) in ethanol (1 ml), the mixture was stirred overnight at 
room temperature. The solvents were evaporated to dryness and dried. A white solid was 
obtained. The same results were obtained and unreacted dibromodilactone was observed 
in the spectrum.
9 0
PART I CHAPTER 3: EXPERIMENTAL
(2) l-M ethvl-8.8-dibrom odilactone with cvsteine
The dibromodilactone (33mg, lmmol) was dissolved in 50% aqueous ethanol 
(7ml) to get a clear solution. To this a clear solution of cysteine (27mg, 2mmol), in 5 ml 
of 50% aqueous ethanol) was added, at room temperature, with stirring. A white solid 
precipitated immediately after the addition. The reaction mixture was left stirring for 
another 2h. The TLC showed that the reaction was complete. The white solid was 
collected.The NMR and mixed melting point with cystine monohydrobromide 
prepared showed that it is cystine hydrobromide. The filtrate was evaporated giving white 
solid. Recrystallisation of this from chloroform gave white crystals, m.p! 78-79 °C, 
flraax 1785 cm-1, 1725 cm -1, 1722 cm -1, 8 (CD3OD, TMS) 1.62 (3 H, s, 3-Me ),
2.51-3.18 (2 H, AB part of ABX, J  18Hz 7Hz 1Hz, 5-H), 5.25 (1H, dd j  7Hz 1Hz, 4- 
H); m!ey 235.07 (C7H7BrC>4 requires 235.01). So this compound was characterized as
2-bromo-3-methylmuconolactone (129).
(3) 4. 4-Dibromomuconodilactone (73) with Cvsteine
The reaction of 4,4-dibromomuconodilactone (73) with cysteine followed the 
same procedure as described in (2). The chloroform soluble white solid was chacterized 
as 2-bromomuconolactone (128) which has been fully characterised by Dr. G.V.Rao. 8 
2.80 (2 H, d, J  7Hz, 5-CH2), 5.42 (1H, dt, /  7Hz 2Hz, 4-H), 7.83 (1 H, d, J  2Hz, 3-
H).
(4) Simple q .a-dibrom o-y-butvrolactone (70) with cvsteine
(a). The dibromolactone (70) (242 mg, 1 mmol) was dissolved in 50 % ethanol 
(15 ml) and cysteine (242 mg, 2 mmol) was also dissolved in 50 % ethanol (25 ml). The 
two clear solutions were mixed together and stirred overnight at room temperature. The 
solvent was evaporated to dryness and the residue was extracted with chloroform. The 
If i NMR spectrum showed that most of the lactone had been recovered, (b) The cysteine
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(242 mg, 2 mmol) was dissolved in 50 % ethanol (25 ml) and triethylamine (101 mg, 1 
mmol) was added (this helps cysteine to dissolve) and this clear solution was added 
slowly to the solution of dibromo compound (70) (242 mg, 1 mmol) in 50% ethanol (15 
ml). A precipitate formed slowly and the mixture was stirred overnight. The work up 
followed the same procedure as before. The NMR spectrum showed that some 
unreacted lactone was still present, (c). Conditions were the same as in (b) but three 
equivalents of cysteine (363 mg, 3 mmol) and two equivalents of triethylamine (202 mg, 
2 mmol) were used. The precipitate formed within 2 min and the mixture was stirred for a 
further 3 h. The precipitate was filtered and dried (154 mg). It was characterized as 
cystine by an NMR spectrum. Evaporation of the aqueous solution gave some white 
solid which was extracted with chloroform. The chloroform soluble portion (375 mg) 
was identified as triethylamine hydrobromide by NMR. The residue left (170 mg) 
was water soluble, m.p. 185-213 °C. TLC showed that it was a mixture and the mass 
spectrum showed that it contained the product (141), mje 205.0413 (C7H 11N O 4S 
requires 205.0409), and cysteine mle 121.0200 (C3H7NO2S). The same product (141) 
was observed by reacting 1 equivalent of 2-bromobutyrolactone (125), cysteine and 
triethylamine. Attempts to isolate them failed in both cases.
3.2 B IO SY N TH ESIS
3.2.1 P seudom onas P utida
M aintenance: Pseudomonas putida (ATCC 12633) (Omston & Stanier, 1966) was a 
stock laboratory culture originally obtained from Torry Reseach Station. It was 
maintained on 1% yeast extract agar slope test-tube at 4 ° C .
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Chemicals; 4-Methylpyrocatechol was purchased from BDH company and all the other 
substrates used were prepared by the author.
General Procedure:
Culture Conditions. - The nutrient medium was prepared as Stanier and Omston with 
some modifications.
Nitriloacetic acid 220mg
Magnesium sulphate hetahydrate 580 mg
Calcium chloride dihydrate 88.5 mg
Ferrous sulphate 7 mg
Ammonium sulphate 1.0 g
Potassium dihydrogen orthophosphate 6.8 g
Disodium hydrogen orthophosphate 7.1 g
Sodium benzoate 1.44 g
Hunter' metal solution '44 ' * 1 ml
Deionised water 1 litre
* Hunter's Metals "44" Solution for O &S Medium.
Ethylene Diamine Tetra-Acetate Disodium Salt
(E.D.T.A. Na 2 • 2H 20)
Zinc Sulphate Hydrate 
Manganese Sulphate Hydrate 
Copper Sulphate Hydrate 
Cobalt Nitrate Hydrate 
Sodium Tetraborate 
Ammonium Molybdate Hydrate 
Deionised Water
318 mg 
1095 mg 
154 mg 
39.2 mg 
24.8 mg 
17.7 mg 
20 mg 
100 ml
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Procedures. - The P . putida (ATCC 12633) slants were maintained on 1% yeast
o
extract agar for 3 d at 25 C. A water suspension of the bacteria was prepared by adding 
2ml of sterile water to the slope and scratching the surface gently to form a suspension. 
The suspension was used to inoculate 3 conical flasks each containing 100 ml of the O/S 
culture medium. The flasks were incubated at 30 °C for 3d with a shaking speed of 160 
r.p.m.. This three day-old culture was then used as inoculum for a different number 
flasks depending on different substrates. Each flask contains 100 ml O/S culture medium. 
These flasks were then incubated at 30 °C with the same shaking speed for 18 h . The 
first batch of the pyrocatechol in sterile deionised water was fed to those flasks. The 
flasks were shaken for 4 h at 30 °C. A ferric chloride test showed that all the 
pyrocatechol had been metabolised. A second batch of the pyrocatechol was then fed. 
The flasks were left shaking overnight (18 h ) .  The ferric chloride test was again negative 
after this second addition, and a third batch of the pyrocatechol in water was fed. After 
another 4h, the cultures were adjusted to pH 7.5 with aq. ammonia and extracted with 
ether to remove non-acidic material. Then the cultures were adjusted to pH 2.5 with 
orthophosphoric acid, saturated with sodium chloride, and extracted with ether to obtain 
the lactone. The ether extracts were filtered through Celite, dried, and evaporated to give 
the target lactone.
(1) B iosynthesis o f 4-methvlm uconolactones
(+)-(4S)-4-MethylmuconoIactone (22). - 4-Methylpyrocatechol (20) (800mg) in 
sterile deionised water (6ml) was fed to 18h-grown cultures of Pseudomonas putida (2 0  
flasks) in three batches following the general procedures. The evaporation of ether 
extracts at pH 2.5 gave the target lactone, (+)-(4S)-4-methylmuconolactone (22) (447mg, 
44%) as oil which failed to crystallise; [ a  ]D = 31.5 °(c, 0.9 in m ethanol); 8 1.57 (3 H,
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s, 4-CH3), 2.68 (1 H, d , J  15.9 Hz, 5 -H r ), 2.92 (1 H, d, /  15.9 Hz, 5-Hs), 6.06 (1 H, 
d , J  5.7Hz, 2-H), 7.66 (1 H, d, J  5.7Hz, 3-H), and  11.0 (1 H, s, COOH).
(45, 55)-4-M ethyl-[5-2H]muconoIactone (65). - 4-Methyl -[3-^H ]pyrocatechol 
(63) (lOOmg) in sterile deionised water (2ml) was fed to 18h grown cultures of 
Pseudomonas putida ( 10 flasks) in three batches and the flasks were shaken for 4h. A 
ferric chloride test showed that all pyrocatechol had been metabolised. The colour of the 
solution had changed to violet-red. One of the flasks was adjusted first to pH 7.5 and 
then to 2.5 with orthophosphoric acid and extracted with ether successively at each pH 
value. The * H NMR spectrum of the extracts at pH 2.5 showed that the product was 
the required monodeuteriated lactone (65). The rest of pyrocatechol (200mg) in water 
(4ml) was fed to the remaining 9 flasks, and the ether extract at pH 2.5 was evaporated 
to dryness giving (45, 55)-4-methylmuconolactone (65) (130 mg, 34%). 8 1.56 (3 H, 
s, 4-CH3), 2.75 (1 H, br s, 5- H s), and 6.10 and 7.65 (2 H, ABq , J  6Hz, 2-H and 3- 
H).
(45)-4-M ethyl-[2-2H]muconolactone (75). - 4-Methyl-[6-^H]pyrocatechol (96) 
(373 mg) was fed in the same way described in general procedure to give the crude (75) 
(90 mg, 19%). Recrystallisation from ethyl acetate-hexane gave the product as a white 
solid; 8 1.57 (3 H, s, 4-CH3), 2.65 and 3.00 (2 H, ABq> J  16Hz, 5-CH2), 6.08 (1 H,
s, 3-H).
(45)-4-M ethyl-[3-2H]muconolactone (66). - 4-M ethyl-[6-2H]pyrocatechol (64) 
was fed to 18h grown cultures of Pseudomonas putida (10 flasks) following the general 
procedure to give the crude lactone, (45)-4-methyl-[3-^H] muconolactone (64) (170 mg, 
34 %) as an oil which failed to crystallise; 8 1.58 (3 H, s, 4-CH3), 2.55 and 2.95 (2 H, 
ABq, /  16Hz, 5-CH2), 7.65 (1 H, s, 3-H).
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(2) B iosynthesis o f 4-ethvlmuconolactnne
(+ )-(4S)-4-E thylm uconolactone (76). - (+)-(4S)-4-E thylm uconolactone (76)
(290 mg in both cases) was obtained in the yield of (53%) and (42%) respectively by
feeding 4-ethylpyrocatechol (76) (450 mg, 560 mg respectively) in sterile deionized
water (10 ml) to 18h grown Pseudomonas putida (10 and 15 flasks respectively) 
following the general proecdure. The product was an oil which failed to crystallise; [ a  ]D
= 14.5° ( c, 0.94 in methanol), 8 0.86 (3 H, t, J  7Hz, CH2-CH 3), 1.95 (2 H, q, with 
fine splitting,/7H z, CH2-CH3), 2.71 and 2.99 (2 H, ABq, J  16Hz, 5-CH?), 6.15 and 
7.58 (2 H, ABq, J  6Hz, 2- and 3-H). The first batch was stored in the fridge while the 
second batch was stored at room temperature. The latter batch cyclised spontaneously to 
give good crystals of the dilactone (132). The crystals were collected (40mg from 260 
mg oil) and recrystallised from ethyl acetate-hexane to give colourless crystals (10 mg); 
m.p. 138-139 °C, [a ]D = 105.2 0 (c, 0.6 in methanol), v max (KBr) 1790cm'1, (-CO-);
Found C 56.39, H 6.11 (CgHjQC^ requires C, 56.46; H, 5.92), mle at 170 (11.6%), 8 
1.0 (3 H, t, J  7Hz, CH2-CH3 ), 2.85 (2 H, q, with fine splitting, J  7Hz, CH2-C H 3), 
2.68 and 2.98 (2 H, ABq, J  20 Hz, 8-CH2), 2.90 (1 H, d, /  3 Hz, 4-H), 4.85 (1 H, t, 
J  3Hz, 5-H). All the data were consistent with the optically pure dilactone (132) prepared 
chemically from (45)-4-ethylmuconolactone (76).
(3) B iosynthesis o f 3.4-dimethvlm uconolactone
3,4-D im ethylm uconolactone (77). - 4,5-Dimethyl-pyrocatechol (82) (560 mg) in 
water (12 ml) was fed to 18h grown cultures of Pseudomonas putida  (10 flasks 
containing 100ml medium each) following the general procedure to give 3,4- 
dimethylmuconolactone (77) (70 mg, 20%) as an oil which failed to cryatallise, 81.57 
(3 H, s, 4-Me), 2.12 (3 H, s, 3-Me), 2.71, 2.96 (2 H, d d j  8Hz, 5-H) and 5.78 (1 H,
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s, 2-H). The structure was established by comparing the spectrum with that of the 
racemic muconolactone prepared from 3,4-dimethyl-6-nitrophenol (123).
3.2.2 Aspergillus Niger
Maintenance; Aspergillus niger EM 32 mutant was originally obtained from 
University of Newcastle-upon-tyne. It was maintained at 4 °C  on Difco bact potato 
dextrose agar slopes in 10ml rubber-sealed bottles. Strains of Aspergillus niger were 
subcultured every six months after which time conidial viability was observed to decrease 
significantly.
Chemicals: 4-methylpyrocatechol was purchased from BDH company and all the other 
chemicals were prepared by the auther.
General Procedure:
C u ltu re  C ondition. - Fungi were grown in liquid culture in a basal salts medium 
containing:
Ammonium sulphate 
Potassium dihydrogen orthophosphate 
Magnesium sulphate heptahydrate 
Trace elements solution *
0.5g
lg
50mg
lml
Deionised water 1L
Glucose 1.8g
* Trace elements solution:
Ferrous sulphate heptahydrate 
Manganous sulphate tetrahydrate 
Zinc sulphate heptahydrate
0.054g
0.04g
0 .02g
.004g
0.004g
Copper sulphate pentahydrate 
Cobaltous chloride hexahydrate
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Potassium iodide 0.03g
Sodium molybdate dihydrate 0.005g
Calcium chloride dihydrate 0.662g
Sodium chloride lg
Deionised water 100ml
The basal salts medium, made up to volume with deionised water, was adjusted to 
pH 5.5 with 1M sodium hydroxide solution and autoclaved at 15ib/in^, 120°C. 
Procedure. - Fresh conidia were obtained by inoculating slope cultures stored onto the 
surface of the fresh potato dextrose agar at 21°C for 3 d. The conidia were washed off 
with Tween 80 solution and suspended in sterile deionised water. The water suspension 
was used to inoculate. A 1 ml inoculum was put into each flask which contained 100 ml 
of the medium. The flasks were incubated at 30 °C for 46 h with a shaking speed of 160 
r.p.m. The utilization of glucose was monitored by U.V. spectrometer.** When the 
glucose almost disappeared, the first batch of catachol was fed and the PH was kept at
5.5 by the addition of sterile 0.5 M dipotassium hydrogen orthophosphate. The flasks 
were kept at 30 °C overnight with the same shaking speed. A ferric chloride test showed 
that all the catechol had been metabolised. A second batch of the catechol was fed and pH 
was adjusted to 5.5 by adding sterile 0.5 M dipotassium hydrogen orthophosphate and 
left shaking for another 26 h. The cultures were adjusted to pH 7.2 with saturated sodium 
bicarbonate and extracted with ether to remove non-acidic material. The cultures were 
adjusted to pH 2.0 with orthphosphoric acid saturated with sodium chloride and extracted 
with ether. Evaporation of ether gave some lactone and the aqueous solution was then 
extracted continously for 48 h to yield more lactone.
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** Colormetric method for determ ination of concentration  of glucose
Glucose is determined by colorimetric method in phenol and concentrated 
sulphuric acid reported by Landa (Ref. 84). The amount of glucose in culture medium 
was determined by reference to the standard curve described as follows.
S tan d ard  curve: -The initial concentration of 180 mg/100 ml was prepared. It was 
diluted to get a different concentration and then 1 ml of aqueous solution was put into 10 
ml volumetric flask. 1 ml of 5% phenol solution was added and mixed. Blanks are 
prepared with 1 ml of water instead of glucose solution. From a fast-flowing pipet (a 
portion of the tip was removed), 5 ml of 95% sulfuric acid was added to each flask so 
that the steam hits the liquid surface directly to produce good mixing and even heat 
distribution. Each flask was shaken during the acid addition, and exactly the same mixing 
procedure was practised throughout. The yellow-orange colour was stable for several 
hours. Absorbances were scanned from 300-700 nm using 0.2 cm x 1.5 cm cell. The 
average absorbance of the blanks is subtracted. The maximum absorbance was located at 
487 nm.
Table 4. UV absorbance of glucose a t 487 nm
Concentration ( mg/100 m l) Absorbance at 487 nm
90 3.040
72 2.562
54 1.729
36 1.069
18 0.783
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4
H experimental data 
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Fig. 2 UV Standard Curve for Glucose
(1) 2.3.4.5-Tetradeuteriom uconolactone (69}. - This compound (69) ( 290 mg, 
56 %) by feeding 2,3,4,5-tetradeuteriopyrocatechol (68) (515 mg) in water (4 ml) in two 
batches to the cultures of A. niger.{15 flasks) 5 (200 MHz) 2.69 (s, 5-H) at pH 7-8.
(2) 3-M ethvlm uconolactone (23). - 4-Methylpyrocatechol (20) (481 mg) in water 
(4 ml) was fed to 3 d old A. niger (15 flasks) in two batches to give 3- 
methylmuconolactone (23) (60 mg, 13 %) as dark grey semisolid (13 %). 5 (D2O, t- 
butanol at 1.22) 2.12 (3 H, s, CH3), 2.40-3.10 (2 H, m, 5-CH2), 5.25 (1 H, m, 4-H),
5.89 (1 H, br s, 2-H). TLC (isopropyl ether/ formic acid/ water at 200:7:3 by volume) 
showed the same Rf (0.25) as that was reported (Ref. 22).
(3) 3-E thvlm uconolactone (134). - 3-Ethylmuconolactone (134) ( 30 mg, 1%) was
obtained, by feeding 4-ethylpyrocatechol (81) (475 mg) in water (10 ml) to 3 d old A. 
niger (15 flasks) in two batches, as a dark oil, which failed to crystallise. 6 (D20 , t- 
butanol at 1.22) 1:18 (3 H, t, CH2CH3), 2.25-2.34 (2 H, m, CH2CH3), 2.52 (2 H, m,
5-CH2), 5.22 (1 H, m, 4-H), and 5.80 ( 1H, br s, 2-H).
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3.2.3 EX PERIM EN TS W ITH 4-M ETHYLM UCONOLACTONE M ETH Y L- 
ISOM ERASE FROM  RHODOCOCCUS RHODOCROUS (carried out 
by Dr. G.V.Rao at University of Newcastle upon Tyne, June, 1989)
G eneral P rocedure . - Frozen cells of Rhodococcus rhodocrous N75 (LA 1069) 
(10 g), grown on p-toluate, were thawed at 4 °C, suspended in tri buffer (50 mM Tris 
hydrochloride, pH 7.0, 10 ml) containing dithiothreitol (0.5 mM), then sonicated at 0 °C 
for 3 min with occasional interruptions to prevent overheating. The resulting suspension 
was centrifuged at -4 °C for 20 min at 16000y to remove cell debris. The supernatant was 
frozen for storage. Portions of this cell extract were heat treated, immediately prior to use, 
at 65 ±0.1 °C for 15 min. Precipitated protein was then removed by centrifugation as 
before (Ref. 44).
(1) (4 £ l- 2 -D e u te r io -4 -m e th v lm u c o n o la c to n e  (66). - (4 S )-2 -D e u te rio -4 - 
methylmuconolactone (66) (11 mg) in sodium phosphate buffer (pH 7.0) (10 ml) was 
incubated with the foregoing, heat treated extract (0.5 ml) at 30 °C. Aliquots (100 pi) of 
the mixture were taken after 0, 5, 10, 20, and 30 min and injected into orthophosphoric 
acid (20 pi). The mixtures were diluted with water to a final volume of 1 ml then were 
centrifuged, as before, to remove precipitated protein. The supernatant solutions were 
analysed by HPLC on a Merck RP-18 LiChrocart column eluted with acetonitrile-water 
(1:9) containing orthophosphoric acid (1 g/1) with a flow rate of 1 ml/min. The 
m uconolactones were detected by their UV absorption at X.215 nm, the 4- 
methylmuconolactone (66) being eluted a little after the product, (4S,5/?)-5-deuterio-3- 
methylmuconolactone (135). The isomerisation was essentially complete in 10 min. The 
mixture was adjusted to pH 1-2 with orthophosphoric acid, saturated with sodium 
chloride, then extracted continuously with ether for 48 h. The *H NMR spectrum (see the
101
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Table) of the total extract (10 mg) showed it to be largely (4S,5R )-5-deuterio-3 - 
methylmuconolactone (138) (anti addition). The mass spectrum confirmed the presence 
of one deuterium atom; mfr 157 (5.7%) (C7H7DO4 requires M, 157), 111 (64.5), 97
(47.8), 69 (95.0), and 41 (100). The other incubations were carried out similarly, as 
follows.
(2) (45. 55)-5-D euterio-4-m ethvlm uconolactone (65). - The substrate (65) (5 
mg) gave (45)-3-methylmuconolactone (23), which contained no significant amount of 
deuterium (anti elimination).
(3) (1 5 .5 5 .8 5 ) -8 -D e u te r io -l-m e th v lm u c o n o la c to n e  (67).- (15 ,55 ,85 ) 8 - 
deuterio-1-methylmuconolactone (67) (1 mg), prepared from the foregoing 5-deuterio- 
muconolactone (65), likewise gave 3-methylmuconolactone (23) with complete loss of 
deuterium.
(4) (4 5 .5 5 1 -2 .3 .5 -T r id e u te r io -4 -m e th y lm u c o n o la c to n e  (41). - (4 5 ,5 5 )- 
2,3,5-trideuterio-4-methylmuconolactone (41) (52mg) gave (45,5/?)-4,5-dideuterio-3- 
methylmuconolactone (136) (57mg) (anti addition and elimination); m/z 158 (1.8%), 
(C7H6D20 4 requires M, 158), 111 (28.5), 98 (22.1), 70 (27.6), 42 (34.8), 18 (100).
(5) (1 5 .4 1 ? .5 5 .8 5 1 -4 .5 .8 -T r id e u te r io - l-m e th y lm u c o n o la c to n e  (140). -
(15,4/?,55,85)-4,5,8-Trideuterio-l-methylmuconolactone (140) (16 mg) (containing 
some of the 45 epimer), prepared from the foregonig trideuteriomuconolactone, gave 
(45,5/?)-4 ,5-dideuterio-3-methylmuconolactone (136) (15 mg) (containing ca. 20% of 
the 5S epimer); m/z 158 (0.4%), 93 (34.8) and 39 (100). In this experiment the cell 
extract was not heat treated before use.
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C H A PTE R
_________ ONE
INTRODUCTION
Part II of the thesis attempts to explore some mechanisms of the biosynthesis of 
the cyclopenin group of benzodiazepine alkaloids in Penicillium cyclopium. This chapter 
will present a general introduction, which has been divided into three sections. Sec. 1.1 
gives a brief review of biosynthetic pathways of benzodiazepine alkaloids. Sec. 1.2 then 
discusses properties of organofluoro compounds with a few examples to highlight the 
specific utility of fluorine in chemistry. The last section, Sec. 1.3, outlines the aims of the 
present project.
1.1 A REV IEW  OF THE BIOSYNTHESIS OF TH E CY CLO PEN IN
G R O U P O F BENZODIAZEPINE ALKALOIDS IN P E N IC ILL IU M  
C Y C L O P IU M
Molds of the genus Penicillium cyclopium synthesize the cyclopenin group 
benzodiazepine alkaloids, which are formed in only a few species of section Asymetrica, 
subsection Fasciculate. The first correct structure of the benzodiazepine alkaloids, 
namely, those of cyclopenin (6) and cyclopenol (7) (Scheme 1), were published in 1963
1 1 0
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by Mohammed and Luckner (Ref. 1). The biosynthetic pathway was investigated in 
surface cultures of Penicillium cyclopium by the radio tracer technique. From feeding 
experiments with 14C labelled phenylalanine, anthranilic acid, or [m ethyl-14C]- 
methionine, and subsequent degradation of the formed cyclopenin and cyclopenol, it was 
found that all the carbon atoms come from anthranilic acid (1) and L-phenylalanine (2) 
and the methyl group of methionine (3) (Refs. 2, 3, 4). The incorporation of 15N-labelled 
precursors revealed that N-l and N-4 of the diazepine ring are derived from the nitrogen 
atoms of anthranilic acid (1) and L-phenylalanine (2), respectively (Ref. 5). L- 
Phenylalanine (2), but neither m-tyrosine, dopa nor tyrosine, proved to be a precursor of 
cyclopenol (7). This suggested that the m-hydroxyl group is introduced into the molecule 
only after the formation of cyclopenin. The incorporation of 180 2  into the hydroxyl group 
is accompanied by a NIH shift, which indicates that the hydroxylation is catalysed by a 
mixed function oxygenase (Ref. 6). Similarly, the incorporation of 180  from 18C>2 into 
the epoxide ring was demonstrated. By a search for intermediates on the biosynthetic 
pathway it was found that beside phenylalanine only two N-methylated cyclic peptides, 
cyc/0-(anthranoyl-N-methylphenylalanyl) (cyclopeptine) (4) and 3,10-dehydro-cyc/o- 
(anthranoyl-N-methylphenylalanyl) (dehydrocyclopeptine) (5), were incorporated into 
cyclopenin without degradation. The non-cyclic peptides, for example anthranoylphenyl- 
alanyl, were not incorporated. It was found that the cyclopenin (6) and cyclopenol (7) 
could be further converted into viridicatin (8) and viridicatol (9) enzymically (Ref. 7). 
These findings established the pathway of cyclopenin-cyclopenol biosynthesis shown in 
Scheme 1. In the first step, the cyclic dipeptide cyclopeptine (4) is formed from 
anthranilic acid (1) and L-phenylalanine (2). The nitrogen atom of phenylalanine is 
methylated at some point by the S-adenosyl derivative of methionine (3). Cyclopeptine
(4), the first free intermediate, is then transformed into 3,10-dehydrocyclopeptine (5). 
The latter is epoxidized to yield cyclopenin (6). This alkaloid is then (at least partially) 
hydroxylated at the meta position of the phenylalanine ring to give cyclopenol (7). The
1 1 2
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formed cyclopenin (6) and cyclopenol (7) then are further degraded by bacteria into 
viridicatin (8) and viridicatol (9) respectively. Chemical degradation of the cyclopenin (6) 
and cyclopenol (7) also led to the formation of viridicatin (8) and viridicatol (9). 
Individual steps (reactions I to V) in the biosynthetic pathway in Scheme 1 will now be 
discussed in more detail.
1 .1 .1  Biosynthesis of Phenylalanine and Anthranilic acid, and Feedback
Activation of their Biosynthesis by Benzodiazepine Alkaloids
The two important precursors, phenylalanine (1) and anthranilic acid (2), can be 
biosynthesized from erythrose-4-phosphate and phosphoenolpyruvate via the shikimate 
pathway before the phase of alkaloid production (Scheme 2) in Penicillium cyclopium. 
They are products of two different branches of this sequence which both originate from 
chorismic acid (Ref. 8). Recently, Ross and Schnauder (Ref. 9) found that cyclopenin 
and cyclopenol substantially stimulate the activation of DAHP synthase (phospho-2-oxo- 
3-deoxyheptonate aldolase), anthranilate synthase, and chorismate mutase when added 
during enzyme incubation and concluded that far-reaching feedback activating effect 
exerted by the benzodiazepine alkaloids rests on a specific property of the primary 
metabolic enzymes like DAHP synthase involved in the biosynthesis of benzodiazepine 
precursor and present during the phase of alkaloid formation. Such a regulatory circuit 
bears an obvious advantage: it enables the cell to increase alkaloid formation without a 
prior increase of the steady-state concentration of the precursor amino acid.
1 .1 .2  The Formation of Cyclopeptine (reaction I)
The absence of any detectable intermediate between the amino acid precursors and 
cyclopeptine and the lack of incorporation of potential intermediates led to the conclusion
1 1 3
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Erythrose-4-phosphate (E-4-P) + Phosphoenolpyruvate (PEP)
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Cyclopeptine
anthranilate
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CH3 (SAM, S-adenosyl- 
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r  Cyclopenin (R=H, 6 )  
Cyclopenol (R=OH, 7)
Scheme 2.
that the first step of cyclopenin biosynthesis is catalyzed by a multienzyme complex, 
which catalyses the activation of anthranilic acid (1) and phenylalanine (2), the synthesis
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of the two peptide bonds and the methylation. Feeding experiments with labelled 
compounds in vivo indicated that the formation of cyclopeptine (4) was indeed catalysed 
by an enzyme complex (cyclopeptine synthetase) with tightly bound intermediates 
(Ref.7). In 1978, Voigt et. al. (Ref. 10) reported that protein extracts from cyclopeptine- 
synthesizing cultures of Penicillium cyclopium catalysed the activation of anthranilic acid
(2) by the ATP-dependent formation of anthranoyl-AMP (AnAMP), probably as part of 
the cyclopeptine (4) biosynthesis (Scheme 3) (Refs. 11, 12, 13).
In vitro, experiments established the following partial activities of a cyclopeptine 
synthetase (Ref. 14), which are summarized in Scheme 3: activation of anthranilic acid 
and L-phenylanine by adenylyl transferase; binding of anthranilic acid and L-phenylanine 
as thioester to protein; and formation of thioester-bound-V-methyl-L-phenylanine and N- 
methyl-L-phenylalanylanthranilic acid. The activation and binding activities were soluble 
after centrifugation at 150,000 g and could be attributed to a high molecular weight 
protein isolated by chromatography on Sepharose 6B. This protein was senstitive to 
mechanical disruption and protease degradation. However, cyclisation of the enzyme- 
bound V-methyl-L-phenylalanylanthranilic acid to cyclopeptine has not been observed 
yet, but in chemical experiments derivatives of anthranylyl-V-methylphenylanine cyclised 
easily to cyclopeptine (4). There are no indications that compounds of this type are 
formed by the enzyme preparation of Penicillium cyclopium.
1 .1 .3  The Conversion of Cyclopeptine into Dehydrocyclopeptine
(reaction II)
Cyclopeptine (4) can be converted into dehydrocyclopeptine (5) with cyclopeptine 
dehydrogenase (Ref. 15). This enzyme is a NAD(P)-dependent flavoprotein which 
catalyses the reversible transformation of cyclopeptine (4) into dehydrocyclopeptine (5) 
by removal of two hydrogen atoms from C-3 and C-10. The activity of this enzyme was 
assayed in a cell-free preparation with NAD(P)+ as the hydrogen acceptor. X-Press and
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acetone treatment proved to be the best methods for cell disintegration. During 
centrifugation the greater part of the enzyme activity sedimented with the cell wall 
cytoplasmic membrane fraction. Cyclopeptine dehydrogenase showed a high degree of 
substrate specificity with respect to functional groups and sterical requirements. During 
tests with analogues, the enzyme was shown to be inactive towards the 10-hydroxy 
derivative of cyclopeptine (4), indicating the importance of the presence of the -CH-CH2- 
group in the molecule. Aboutabl et al. (Ref. 16) further investigated the stereochemical 
aspects of this conversion. To decide which of the two hydrogen atoms of the C-10 
methylene group is removed during the dehydrogenation, they prepared specifically 
tritium labelled cyclopeptines, (14a) and (14b) from benzaldehyde-[formyl-^H] (11) as 
a tracer by the route outlined in Scheme 4.
O
( 10) ( 11 ) ( 12 )
n O
NH2 c ° 2 h
n h 2
(13a) (13b)
n O
3S-[ 10/f-3H,] (14a)
Scheme 4.
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Ar-(<9-Nitrobenzoyl))-Ar-m ethyl-a-am ino-[3 '-^H ]-cinnam ic acid (12) was 
synthesized by condensation of [ f o r m y l- ^ H ]  benzaldehyde (11) with o-nitrobenzoyl- 
sarkosine (10). Hydrogenation of this compound (12) with platinum catalyst gave, by 
the usual ds-addition of hydrogen (Refs. 17, 18), the two isomers of labelled N-(o- 
aminobenzoyl-N-methylphenylalanine, (13a) and (13b), which by treatment with acid, 
cyclised to a mixture of two isomers of cyclopeptine (14a) and (14b), labelled at position
10. The compounds (12), had the fra/zs-configuration, as established by NMR analysis. 
Of the two isomers present in the radioactive cyclopeptine preparation only the 3S-[\0R- 
^H]-compound (14a) was a substrate of cyclopeptine dehydrogenase and the tritium 
atom remained during the dehydrogenation. Thus cyclopeptine dehydrogenase removed 
the pro-S  hydrogen from C-10 to give Z-dehydrocyclopeptine (5) by a sy«-periplanar 
elimination.
1 . 1 . 4  The Formation of Cyclopenin (reaction III)
Dehydrocyclopeptine (5) can be enzymically converted into cyclopenin (6) by 
dehydrocyclopeptine epoxidase (Ref. 19). Tracer experiments performed in living cells 
demonstrated that the epoxide oxygen present in the molecule of cyclopenin (6) and 
cyclopenol (7) is derived from molecular oxygen, indicating that it works as a mixed 
function oxygenase (Refs. 5, 20), using NAD(P)H or other reducing compounds such as 
ascorbic acid and DL-methyl-5,6,7,8-tetrahydropteridine directly as hydrogen donors. 
The enzyme activity was assayed by following the rate of cyclopenin formation from H- 
labelled dehydrocyclopeptine (5). The radioactivity of this product was determined after 
converting it into viridicatin, which was chemically oxidized to 2-aminobenzophenone. 
The highest specific activity of dehydrocyclopeptine epoxidase was measured after 
acetone treatment of hyphal cells and coridiospores. More than one-third of the 
measurable activity sedimented with the cell wall plasma membrane fraction, from which
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it could be solubilized by a 1 % solution of deoxycholate. The soluble enzyme fraction 
was purified by ammonium sulfate precipitation and gel chromatography, and its 
molecular weight was estimated to be near 500,000 daltons. Inhibitor experiments 
indicated that the enzyme is an Fe^+-activated, FAD-containing flavoprotein.
The first total synthesis of cyclopenin (6) by Rappoport and colleagues (Scheme 
5) (Ref. 21a and b) started with 2-amino-A-methylbenzamide (15), which was treated 
with trans-cinnamoyl chloride (16) to give the cinnamanilide (17). The latter was 
epoxidized with m-chloroperbenzoic acid to the p-phenylglycidamide (18). Ring closure 
with potassium rm-butoxide in tert-butanol yielded the hydroxyl compound (19). After 
this product was acetylated, the O-acetyl derivative (20) was converted by heating into 
cyclopeptine (5). The final, most complicated step was the epoxidation of the benzylidene 
compound (5) with m-chloroperbenzoic acid (at room temperature for 14 days) to yield 
(±)-cyclopenin (6), as proved by spectral comparison with the natural product. During 
this procedure the relative stereochemistry of the trans-cinnamate is retained and hence 
only one stereoisomer of cyclopenin (6) is produced. In this way, the relative 
stereochemistry for cyclopenin was confirmed. Richter et. al. (Ref. 22) synthesized the 
P-phenylglycidamide (18) by reacting A-chloroacetyl-A-methylanthranoyl amide (21) 
with benzaldehyde.
1.1.5 Cyclopenin m -hydroxylation (reaction IV)
In vivo, incorporation of oxygen from ^ 0 2  into hydroxyl group of cyclopenin 
revealed that the hydroxylation is catalysed by a mixed function oxygenase. In vitro, a 
partially purified enzyme (by ammonium sulphate precipitation and calcium phosphate gel 
treatment) was used to test different substrates. It was found that hydroxylase like 
cyclopeptine epoxidase it acts as a mixed function oxygenase which reacts with molecular 
oxygen and requires a hydrogen donor [NAD(P)H, ascorbic acid, tetrahydropteridine] as 
cosubatrate. Cyclopenin m -hydroxylase was not inhibited by CO (Ref. 23). This may
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indicate that the enzyme does not belong to the group of mixed function 
oxygenase which contains a cytochrome P-450 moiety. The decrease of enzyme activity 
after addition of dicoumarol, an inhibitor of flavin protein, indicates that m-hydroxylase 
belongs to this group of proteins, KCN and KCNS inhibit the enzyme activity too. All 
tested benzodiazepines were transformed into the hydroxyl derivative by cyclopenin m-
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benzodiazepines were transformed into the hydroxyl derivative by cyclopenin m- 
hydroxylase preparations. Cyclopenin hydroxylation had the highest velocity. The 
quinoline derivative viridicatin was not attacked.
During aromatic hydroxylation the epoxide intermediates are unstable and 
rearrange to the hydroxy compounds via carbonium ions which are usually stabilized by a 
1,2-anionotropy, the NIH shift (Ref. 20). This process results in a translocation of the 
hydrogen replaced by the hydroxyl group to the 0-position. To characterize the m- 
hydroxylating enzyme system participating in cyclopenol biosynthesis, experiments with 
specifically ring-tritiated DL-[carboxyl-^C]phenylalanine were performed. Only with m- 
T-DL-[carboxyl-l^C]phenylalanine did a change of the T /^ C  ratio in cyclopenol occur, 
though more than half of the T-label is retained, namely ca. 70% in two independent 
experiments. This indicated a partial NIH shift of tritium (ca. 30%) after attack at a 
tritiated meta position. In addition to the alkaloids the isolation of L-tyrosine also gave the 
good evidence for the NIH shift study.
1.1.6 Benzodiazepine-Q uinoline Conversion (R eaction V)
The enzyme, named cyclopenase which was obtained from conidiospores of 
Penicillium cyclopium and Penicillium viridicatum, is able to convert the alkaloids 
cyclopenin (6) and cyclopenol (7) produced and excreted by these fungi to the quinoline 
alkaloids viridicatin (8) and viridicatol (9), respectively (Refs. 24, 25). The enzyme is 
located at the cytoplasmic side of the conidiospore plasma membrane, therefore 
significant ammounts of viridicatin (8) and viridicatol (9) occur solely in the conidia but 
not in the culture medium (Refs. 26,27). Nearly all the cyclopenase activity was found in 
a fraction containing the cell wall together with the cytoplasmic membrane (Refs. 28,29). 
The specificity of the enzymatic catalysis is indicated by the very low conversion rate of 
the artificial substrates N - 1 -methylcyclopenin, N-l-ethylcyclopenin and N,0-dimethyl- 
cyclopenol compared with cyclopenin and cyclopenol (Refs. 28). In contrast, the
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nonenzymatic, acid-catalyzed conversion of the benzodiazepines to the quinoline proceeds 
at similar rates in both the natural and alkylated cyclopenin derivatives .
The formation of quinoline alkaloids from cyclopenin (6) and cyclopenol (7) can 
be catalysed either by cyclopenase or by treatment with acid or alkali. Enzymatic and acid- 
or base-catalyzed reactions show close parallels. The conversion involves the liberation of 
CO2 , which derives from the C-5 carbonyl group, and of methylamine, which contains 
the N-CH3 group in position 4 of the benzodiazepine nucleus. This attribution of the 
reaction products was found by subjecting specifically labelled cyclopenin to 
cyclopenase- or acid-catalyzed conversions (Ref. 24) and was confirmed by the results of 
cyclopenin-viridicatin conversion under anhydrous conditions, that is, during thermal 
degradation, during mass spectrometry, and under the influence of Lewis acids in 
nonaqueous solvents (Ref. 24, 30, 31). In all the latter cases, the formation of viridicatin 
(8) is accompanied by the liberation of methylisocyanate. This compound, which in 
aqueous solution immediately yields CO2 and NH2CH3, is therefore suggested to be 
primarily extruded from the cyclopenin molecule. The reaction involves no incorporation 
of hydrogen or oxygen from water, as demonstrated in the presence of either ^H2 0  or 
H2 I 8 0 . This finding demonstrates, that the closure of the heterocycle of the quinoline 
nucleus occurs between C-5a and C-10 of the benzodiazepine and that the epoxide 
oxygen of cyclopenin becomes the 3-hydroxyl oxygen of viridicatin.
A mechanism for the transformation of the benzodiazepine to the quinoline 
structure, which accounts for all data obtained from both cyclopenase- and acid- or base- 
catalyzed reactions, has been proposed by White and Dimsdale (Ref. 32) (Scheme 6). 
The conversion is induced by attack of an electron acceptor {e.g., H+) at the epoxide 
oxygen or by attack of an electron donor {e.g., OH-) on the N -l atom. Bond formation 
between C-10 and C-5a of cyclopenin is facilitated by the close approach of these two 
atoms in the boat conformation. Therefore, the formation of a tricyclic intermediate 
appears likely, although a compound of this type has not been isolated so far. Another
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mechanism that would explain the enzymatic and acid-catalyzed conversions was 
proposed by Luckner and Nover (Ref. 3).
SC
H
Cyclopenin
0 = C = N - C H 3 
Schem e 6.
Viridicatin
- co2 + h 2n c h 3
In 1980, Luckner (Ref. 33) gave a very detailed review of alkaloid biosynthesis in 
Penicillium cyclopium from the biological point of view and concluded that the formation 
of the alkaloids of the cyclopenin-viridicatin group exhibits some of the most 
characteristic features of secondary product formation, i.e. restriction of the synthesis of 
the alkaloids to a limited group of organisms; formation by specific enzymes; strict 
regulation of the amount and in vivo activity of the enzymes; compartmentation of 
enzymes, precursors, intermediates and products; and lack of significance for the 
synthesizing cell itself, but possible importance for the producer organism as a whole.
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1.2 CH EM ISTRY  OF ORGANOFLUORINE COM POUNDS
Almost one hundred years ago in 1896, the synthesis of methyl fluoroacetate by 
heating methyl iodoacetate with silver fluoride was first described by a Belgian chemist, 
Swarts (Ref. 34), who heralded the beginnings of modem organofluorine chemistry and 
laid good foundations for all subsequent organofluorine chemistry. The introduction of 
fluorine into organic compounds can cause a variety of very significant changes in their 
chemistry, for instance organofluorine compounds have been widely used as coolants, 
e.g. CF3BU aerosol propellants, e.g. CCI2F2; polymers, e.g. polytetrafluoroethylene; 
anaesthetics, e.g. C F 3CHClBr; and rather exotically as blood substitutes, e.g. 
perfluorodecalins and polyfluorocyclohexane. In this last role the fluorocarbons act as 
efficient transporters of both oxygen and carbon dioxide, and can substitute for blood 
where blood is not readily to hand, as in battlefield situations. The following brief review 
will illustrate a few of the properties of organofluorine compounds in biological system 
selection of typical examples.
1 .2 .1  The P roperties of Fluorine
The biological effects of introducing fluorine into organic molecules have been 
studied widely since 1943 when Marais demonstrated that the toxicity of the South 
African plant Dichapetalum cymosum was due to fluoroacetic acid (Ref. 35). This 
discovery provided the impetus for studies on the toxicology and pharmacology of 
organofluorine compounds. The unique physical properties of fluorine that make it 
particularly useful in this area (Ref. 36, 37, 38) are cited below.
(i) The strength of the carbon fluorine bond exceeds that of the carbon hydrogen 
bond (Table 1). This often results in increased thermal and oxidative stability of 
organofluorine compounds (Ref. 39).
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Table 1. Bond Energy
X H F Cl Br 1 I
bond energy 
CH3-X, kcal mol'l
104 109 24 70 1 56
(ii) Fluorine is the smallest atoms that can replace hydrogen in organic compounds 
with the formation of a stable covalent bond (Table 2). Consequently it closely mimics 
hydrogen with respect to steric requirement at enzyme receptor sites (Ref. 39).
Table 2. van der Waals radius and Bond Length
van der Waals radius (A) bond length (A)
F 1.35
H 1.10
C-F 1.26-1.41
C-H 1.08-1.11
(iii) The high electronegativity of fluorine (4.0 on the Pauling scale) frequently 
alters the electronic properties and thereby the chemical reactivity of the compounds 
concerned. It may function as H-bond acceptor, and replacement of a hydroxyl group by 
fluorine often has interesting results. In addition it is a moderately good leaving group 
and may be displaced by nucleophile at or near to the active site of enzymes, with 
resultant covalent attachment of an organic molecule to the enzyme.
(iv) The introduction of fluorine into organic molecules usually increases their 
lipid solubility, thereby enhancing the rates of absorption and transport of drugs in vivo.
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The trifluoromethyl group is one of the most lipophilic group known. This feature is of 
considerable importance in drug design.
(v) Like hydrogen, 19f  has a magnetic spin of 1/2. This property makes fluorine 
NMR spectroscopy a powerful analytical technique in chemistry. Fluorine NMR 
spectroscopy has a number of advantages. Fluorine has a detection sensitivity nearly as 
great as that of hydrogen; chemical shift and substituent effects are frequently an order of 
magnitude larger than those for hydrogen; and the fluorine NMR resonance can be 
observed without interference from background protein NMR resonances or resonances 
from secondary metabolites. Therefore it is widely used in the analysis of biological 
systems.
1 .2 .2  E xam ples
All of these above features, either individually or in combination, will influence 
the outcome of a reaction (whether enzyme-catalysed or not) in which a fluoro analogue 
of the natural substrate is employed and it is instructive to consider some compounds 
which exemplify these effects. The methods of fluorine insertion into organic compounds 
have been summerized in great detail by Mann in 1987 (Ref. 40).
The introduction of fluorine into organic molecules often results in profound 
changes in chemical or biological activity. Consequently this technique has been used to 
develop many classes of drugs with a wide range of biological activities. One method of 
drug design is to select a crucial intermediate of a key biological reaction which is also of 
special importance to a 'disease process' (Ref. 41, 42). Having identified a suitable 
intermediate the next step would be to prepare synthetically an 'anti-metabolite'; that is to 
prepare a compound that resembled the metabolite very closely, but be different enough to 
block or inhibit the selected biological process. To accommodate this idea the term 
'isogeometric modification' was used to describe the required chemical change. 
Naturally, the similarity in size between hydrogen and fluorine but their drastically
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different chemical properties made the use of fluorine an obvious choice for 'isogeometric 
modification'. These ideas led Kollonitsch and co-workers (Ref. 41) to synthesize 3- 
fluoro-D-alanine. It is a antimetabolite of D-alanine, which is an important constituent of
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bacterial cell wall. 3-Fluoro-D-alanine proved to have a wide spectrum of antibacterial 
activity both in vitro and in vivo. Subsequently it was proved that the fluoroalanine did 
act as an anti-metabolite by being an irreversible inhibitor of the enzyme alanine racemase 
(Ref. 43). The mechanism for this enzyme inhibition is shown in Scheme 7. The loss of 
HF from the aldimine (22) formed between fluoroalanine and the pyridoxal phosphate 
(PLP) moiety of the enzyme gives an enamino-PLP complex (23). The key property of 
this complex is that it is electrophilic and thus it is capable of reacting with nucleophile. 
This complex (22) could either be hydrolysed to pyruvate and ammonium ion or be 
attacked by enzyme bound nucleophile, e.g. terminal amino group of a lysine residue to 
form alkylated and hence irreversibly inhibited enzyme.
Another fascinating example that is frequently cited is the anti-metabolite, 5- 
fluorouracil, as an anti-cancer drug (Scheme 8) (Ref. 44). There are two different 
mechanisms for the cytotoxicity of 5-fluorouracil. The size of the fluorine atom allows the 
fluoro compound to mimic uracil. Consequently, it is enzymatically converted into the 
nucleotide 5-fluorouridine (24) and then into 5-fluorouridine, di- and tri-phosphate 
(Refs. 45, 46, 47, 48). The triphosphate (25) is incorporated into RNA, which is 
believed to cause transcription errors within the developing tumor cells leading to 'lethal 
synthesis'.
A
H
(24)  
Scheme 8.
h o h 2c
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More clearly understood, however, is the inhibition of the enzyme thymidylate 
synthetase (Ref. 46) which catalyses the process shown in Scheme 9, whereby 
deoxyuridylate (26, X=H) is methylated to produce deoxythymidylate (29). It 
wasbelieved that the process proceeds via a Michael addition of a thiol group from 
enzyme to the uracil moiety (26), followed by electrophilic addition of Af5’Af10- 
methylene-tetrahydrofolate. The process is completed by elimination. Clearly if 5- 
fluorouracil has been incorporated into the deoxyuridylate (26, X=F), this final step 
requires abstraction of F+ which is unlikely. Since formation of deoxythymidylate is 
essential for DNA biosynthesis, 5-fluorouracil is an effective cytotoxic agent, and is 
much used in cancer chemotherapy.
The following example highlights the investigation of a biological reaction by 
fluorine NMR spectroscopy. Lysozyme is a small enzyme (mol. wt. 14,400), which is 
characterized by its high stability and ability to lyse the cell walls of susceptible bacteria 
(Ref. 49). Hen egg white lysozyme is the most studied variant of the protein. A nember 
of mono-, di-, and tri-saccharides are inhibitors of this enzyme. They act competitively 
with the substrate at one or more of the binding subsites. A lot of experiments using 
fluorine NMR spectroscopy with fluorine-containing saccharides in the presence of the 
enzyme have been reported. One example is the binding of the trifluoroacetylated 
analogue of chitotriose to lysozyme (Ref. 50).
The signal of a one- to one mole ratio of enzyme to trisaccharide, each at 3mM is 
shown in Scheme 10 at three pH values (Ref. 51). The sharp peak at highest field 
concentration is due to the trifluoroacetate anion, which was used as an internal reference. 
Assignments were made on the basis of experiments at higher temperatures(65°C) and at 
pH4 under conditions of fast exchange with excess trisaccharides present, and also by 
comparison with the spectra of the pure trisaccharide. In the spectra at pH 4.5, the bound 
inhibitors resonances are assigned as follows:the resonance at lowest field corresponds to 
the trifluoroacetyl (F3Ac) group at the non-reducing end of the trisaccharide; the one next
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19F NMR Spectra of Solutions of 3mM T rifluoroacety lated Chitotriose 
and 3mM Lysozyme at 10°C at Three pH Values
pH  7-25
pH  4-50
pH  3 00
150 H z
Scheme 10.
to high field corresponds to the F3AC group at the reducing end of trisaccharide (this 
resonance separates into a -  and P-anomeric forms at pH>7.25); the other resonance 
corresponds to the middle F3AC group of the trisaccharide. The effects of pH on the 
position of the resonance was studied and the results showed that the pH depence of the 
shift of the non-reducing F3AC end group implies a group with pKa of 3.2. This is 
identified as Asp-101 in the top of the lysozyme-binding cleft, since the pKa of this group 
in the enzyme (4.2) changes to 3.6 upon binding of chitotriose and further, a group of 
pKa 4.2 in the enzyme changes to 3.2 on binding F3Ac-chitotriose.
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The interaction of chitotriose (30) with specific groups on the enzyme, as 
determined by X-ray analysis are shown in Scheme 11 (Ref. 52). If the fluorinated 
analogue binds similarly, the formation of a hydrogen bound between Asp-101 and F3AC
apparent that the F3AC group at the reducing end of the trisaccharide is the furthest F3AC 
group from Asp-101, and yet, unlike the central F3AC group, it experiences an obvious 
chemical shift. The origin of the shift is unlikely to be electronic, as is that for the F3AC 
group at the non-reducing end. If however the formation of the Asp-101 hydrogen bond 
causes a conformational change in the complex such that the position of the reducing end 
of the trifluoroacetamido group is shifted with respect to the aromatic ring of Try-108. 
The difference in ring-current effects could account for the observed shift.
group would give a change in the ^ F  chemical shift of this group. From the model, it is
Try-62 Try-63
H
59
Asp-52 — C=C
O
CH2OH
H3C -C -N H I I— 0Hc h 2 h n - c —c h 3
1 •% 11O -H  \  o  % »
(4.5) 11o
Asp-101 (4.2-3.7)
SGlu-35
(6.0-6.5)
Scheme 11.
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Some attention has also been paid to the microbial metabolism of fluorine 
substituted compounds. The microbial metabolism of fluoroglucose is a typical example 
(Scheme 12). In 1972, Taylor et al. (Ref. 53) demonstrated that 3-deoxy-fluoro-D- 
glucose (31) was metabolised by whole resting cells of Pseudomonas fluorescens, with 
retention of the C-F bond, to produce 3-deoxy-3-fluoro-D-gluconic acid (32). Cell-free 
extracts of this organism further oxidised compound (32) further to 3-deoxy-3-fluoro-2- 
keto-D-gluconic acid (33). It has also been shown that the same enzymes which oxidise 
D-glucose (glucose oxidase and gluconate dehydrogenase) also oxidise (31), and that 
(31) and (32) are competitive inhibitors of the enzymes (Scheme 12) (Ref. 54).
The biochemical effects of the isomeric 4-deoxy-4-fluoro-D-glucose (34) on 
whole resting cells (Scheme 13) and cell-free extracts (Scheme 14) of Pseudomonas 
fluorescens were examined by Taylor et al. (Ref. 55). They reported that compound 
(34), unlike (31), is not oxidised by whole cells but that there is an immediate release of
CH2OH
Pseudomonas fluorescens
c o 2h
H OH
F  H
whole resting cells or 
cell free extracts H OH
H OHOH
(3 1 )
F— j— n
H OH
H OH
Ps. fluorescens 
cell-free extracts
CH2OH
(33)
Scheme 12
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a fluoride anion (Scheme 13). The possible defluorinated products of this reaction were 
4-deoxy-D-glucose and 3,4-anhydro-D-glucose, which were identified by TLC analysis 
of the cell supernatants and intracellular contents. When cell-free extracts of 
Pseudomonas fluorescens were incubated with 4-deoxy-4-fluoro-D-glucose (34) no 
significant defluorination occurred. Analogous to 3-deoxy-3-fluoro-D-glucose (31), 4- 
deoxy-4-fluoro-D-glucose (34) is converted into 4-deoxy-4-fluoro-D-gluconic acid (35) 
and 4-deoxy-4-fluoro-2-keto-D-gluconic acid (36) respectively by glucose oxidase and 
gluconate dehydrogenase via the two-step oxidation (Scheme 14). The extensive 
defluorination of (34) by whole cells of Pseudomonas fluorescens and retention of the C- 
F bond on the treatment of (35) with cell-free extracts suggested that C-F cleavage occurs 
at the cell-wall/membrane level of the organism. A glucose transport system might be 
present in Pseudomonas fluorescens and the failure of the whole cell to oxidise 4-deoxy-
4-fluoro-D-glucose (34) might be due to a special reaction in which co-valently bonded 
fluorine is release as fluoride ion.
3,4-anhydro-D-glucose 4-deoxy-D-glucose
Scheme 13.
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Clearly introduction of fluorine into a compound can have a marked effect upon 
its biological activity. The use of fluorine to probe the mechanism of enzymatic reactions 
is a promising technique. The examples presented have been chosen in an attempt to 
highlight these characteristics of fluorine.
1 .3  AN OUTLINE OF THE PRO JECT
It has been seen from the above review that some aspects of alkaloid metabolism 
in Penicillium  cyclopium  are now relatively well known, in terms of chemistry, 
biochemistry and enzymology, whereas some other aspects are still obscure. In 
particular, the mechanism of meta hydroxylation of the phenyl ring of cyclopenin, which 
results in a partial NIH shift of hydrogen (tritium) is not well understood. The 
introduction of fluorine into organic compounds can cause dramatic changes in chemical 
and physical properties, as illustrated above. Therefore, the present project attempted to
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investigate the influence of the fluorine atom on the w-hydroxylation of cyclopenin. Due 
to the poor growth of the stock strain of Penicillium cyclopium Westling and the limited 
time, only preliminary experiments were possible. The following four compounds were 
synthesized to as precursors of the biosynthesis cyclopenin and cyclopenol in Penicillium 
cyclopium.
(±)
X = H (37)
X = m -F (39)
X = p-F  (40)
Scheme 15.
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C H A PTER
____________________T W O
RESULTS AND DISCUSSION
Chapter two begins with a discussion of the synthetic methods for the preparation 
of fluorophenylalanines in Sec. 2.1. The biotransfromation of fluorophenylalanines into 
benzodiazepine alkaloids, which is then presented in Sec. 2.2. and finally, some 
conclusions are drawn in Sec. 2.3.
2 .1  C H EM IC A L SYNTHESIS OF PHENYLALANINES
Although phenylalanine (37) and fluorine-substituted phenylalanines, (38), (39), 
and (40), are commercially available now, the following route (Scheme 16) was 
designed for the preparation of radioactive phenylalanines and was used to prepare 
supplies of the unlabelled amino acids for the feeding experiments.
The reaction of benzaldehyde (41) with glycine (45) or acetylglycine (46) (which 
was prepared from glycine and acetic anhydride (Ref. 56)), in acetic anhydride in the 
presence of sodium acetate resulted in the formation of the azlactone of a -  
acetaminocinnamic acid (47) (Ref. 57). It was found that different yields were obtained 
by using glycine and acetylglycine respectively as starting material. Acetylglycine gave a 
20% higher yield of the azlactone than glycine itself. The crude azlactone (47) obtained, 
without purification, was hydrolysed by refluxing with acetone-water to give a -  
acetamino acid. It was reported that a-acetamino acid (51) could be hydrogenated by 
high pressure hydrogenation in acetic acid with platinum oxide as catalyst to yield N-
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Scheme 16.
acetylphenylalanine (55). We preparecW-acetylphenylalanine (55) in good yield 
from the acetaminocinnamic acid (51) by hydrogenation over 10% palladium-carbon in 
ethanol at standard pressure and temperature. The N-acetylphenylalanine (55) was then 
heated under reflux in dilute hydrochloric acid to effect hydrolysis. The DL-phenylalanine
(37) was precipitated by carefully adjusting the pH of the aqueous solution with 
concentrated hydrochloric acid and ammonium hydroxide (Ref. 58).
The corresponding fluoro derivatives, (38), (39), (40), were then prepared 
similarly.
1 3 8
PART II CHAPTER 2: RESULTS AND DISCUSSION
2.2 BIOSYNTHESIS OF CYCLOPENINS AND CY CLO PEN O LS
Penicillium cyclopium (CMI 89374) was grown under the same conditions as 
Braken et al. reported in 1954. Attempts to produce high yields of metabolites failed. The 
three fluorine substituted phenylalanines were fed in parallel in one portion to 6 days old 
cultures of Penicillium cyclopium with minimum disturbance of the mycelium. Incubation 
was continued for another 10 days at 25 °C (Scheme 17). The mycelium mat was 
removed from the top of each culture. The culture medium was then extracted three times 
with distilled ethyl acetate three times, without prior adjusting of the final pH. The 
extracts were dried and evaporated to yield an oil, which failed to crystallise, TLC
r
o
C ' CH3 / “ \oo¥^
- O '
c h 2- c h - c o 2h
NH2 P. cyclopium .   -■
X = H (37)
X  = o-F (38) 
X = m-F (39) 
X = p-F (40)
O
X = H (6)
X = o-F (59) 
X  = m-F (60) 
X = p-F  (61)
X = H (7)
X  = o-F (62) 
X = m-F (63) 
X = p-F (64)
Scheme 17.
showed weak spots running alongside those of reference samples of cyclopenin (6) and 
cyclopenol (7), except with p-F phenylalanine substrate, but preparative TLC did not 
yield any useful quantities of the metabolites. However the mass spectra of the total
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extracts showed them to contain the natural metabolites together with small amounts of 
the expected fluoro metabolites. These results are detailed in Table 3 and 4.
2.3 C onclusions
The present research provided some supplementary results for investigations of 
the biosynthesis of benzodiazepine alkaloids and microbial metabolism of fluorine 
substituted compounds. Three fluorophenylalanines were incorporated by Penicillium  
cyclopium into benzodiazepine alkaloids, cyclopenin and cyclopenol, resulting in the 
formation of corresponding fluorocyclopenin and fluorocyclopenol. Scaling up these 
experiments and feeding optically pure substrates to obtain enough material for 
quantitative analysis remains to be done. Separation techniques with high senitivity, such 
as HPLC, could then be applied. Because the yields of cyclopenin and cyclopenol were 
much lower than those previously obtained with this organism, deductive conclusions 
were reached by mass spectra analysis. In addition to normal metabolites, cyclopenin, (6) 
and (7), fluorocyclopenin and fluorocyclopenol (possible) were observed with feeding 
experiment of o-F phenylalanine (38); fluorocyclopenin but no fluorocyclopenol (might 
be due to the too low yield) were observed with m-F phenylanine (39); fluorocyclopenin 
(possible) but no fluorocyclopenol at all in both two experiments were observed with p-F 
phenylalanine (40). There was no evidence which can provide some information of the 
location of the fluorine.
Due to the limitation of the purity and quantity of metabolic products produced 
during the present research, 19F NMR spectroscopy could not be used to characterise the 
metabolite. This can be developed in future research. Further, larger concentrations of the 
substrates (the concentration of the substrates in the present experiments were less than 5 
mM) could be applied to see whether these fluoro-phenylalanines act as inhibitors for the 
growth of the organism and / or the production of the secondary metabolites.
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C H A PTE R
THREE
EXPERIM ENTAL
3 .1  C H EM IC A L SYNTHESIS OF PHENYLALANINES
Acetylglycine (46).- In a 1 L conical flask were placed glycine (75g, 1 mol) and water 
(300 ml). The mixture was stirred vigorously unitil the glycine had almost completely 
dissolved, then acetic anhydride (98%, 215 g, 2 mol) was added in one portion. 
Vigorous stirring was continued for another 30 min, during which the solution became 
hot and acetylglycine (46) began to precipitate out. The reaction mixture was left 
overnight at room temperature to effect complete precipitation. The white precipitate of 
acetylglycine was collected, washed with ice-cold water and dried over phosphorous 
pentaoxide, m.p. 207-208.5 °C (lit. 207-208 °C). The product was used directly without 
further purification. The combined filtrate and washings were evaporated to dryness 
under reduced pressureto yield additional product, the total yield was 90%.
a-Acetaminocinnamic acids.- General method: A mixture of acetylglycine (5.85g,
0.05 mol), anhydrous sodium acetate (3.01 g, 0.037 mol), freshly distilled benzaldehyde 
(7.9 g, 0.074 mol) and acetic anhydride (134 g, 0.125 mol) in a round-bottomed flask 
fitted with a condenser and a drying tube was warmed on the steam bath with occasional 
stirring until solution was complete, ca.y 15 min. The resulting solution was boiled for 
one hour under reflux, cooled and placed in a refrigerator overnight. The resulting solid 
mass of yellow crystals was treated with 50ml of cold water and broken up with a stirring
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rod. The crystals were then collected and washed thoroughly with sufficient cold water 
and dried to give the crude azlactone. The azlactone was used for further hydrolysis 
without further purification.
The crude azlactone of a-acetateminocinnamic acid (4.7 g, 0.025 mol) was 
dissolved by boiling in a mixture of acetone and water (2.5/1, v/v). Hydrolysis was 
completed after refluxing for 4 h. Most of the acetone was then removed under reduced 
pressure. The residual solution was diluted with water (40 ml), heated to reflux for 10 
min to ensure complete solution of the acetamino acid, and filtered. The undissolved 
material which remained on the filter paper was washed with boiling water. Any crystals 
which separated from the filtrate were redissolved by heating, after that the solution was 
boiled for with charcoal for 5 min and then filtered with the aid of gentle suction while 
still at the boiling point. The charcoal was washed thoroughly on the funnel with boiling 
water to remove the crystals which separated during the filtration and the washings were 
added to the main filtrate. After standing in a refrigerator overnight the light coloured 
crystalline needles were collected and dried under vaccum to yield the target product, a - 
Acetaminocinnamic acid.
The characterization data for the four analogues of a-acetaminocinnamic acid 
prepared, (51), (52), (53), and (54) are listed in Table 5.
Phenylalanines. - General method: A solution of a-acetateminocinnamic acid (2.05g, 
10 mmol) in ethanol (150 ml) was place in a round-bottomed flask and stirred under a 
hydrogen atmosphere with 10% palladium-carbon (205 mg, 10% by weight) until the 
calculated amount of hydrogen had been taken up (about 230 ml). The catalyst, 
palladium-carbon was removed by filtration and washed with a sufficient amount of 
ethanol. The combined filtrate and washings were evaporated to dryness under reduced 
pressure on a water bath and the residue was hydrolysis directly without further
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purification. The N-acetophenylalanines, (55), (56), (57), and (58), were obtained in 
good yield (Table 6).
The residue was taken up in IN hydrochloric acid (40 ml) and refluxed overnight. 
The resulting solution was evaporated to dryness and the residue was dissolved in boiling 
water (40 ml). The pH of the solution was adjusted until it was basic to Congo red,but 
still acid to litmus, by careful addition of concentrated ammonia and acetic acid. Then two 
volumes of absolute ethanol was added to aid the separation of phenylalanine. The 
mixture was placed in the refrigerator overnight to complete the cryatallisation. The solid 
was collected and washed with ice-cold water and absolute ethanol. Pure phenylalanine 
was obtained.
In total four phenylalanines, (37), (38), (39), and (40), were prepared by the 
methods described above and listed in Table 7.
3 .2  BIOSYNTHESIS OF CYCLOPENINS AND CY CLO PEN O LS IN 
P E N IC IL L IU M  CYCLOPIUM
C h em ica l s :  Three precursors, o -F phenylalanine, m -F phenylalanine, and p -F  
phenylalanine were prepared by the author as described in Sec. 3.1. and the other 
chemicals were obtained from commercial purchase at the analytical grade.
M aintenance: The strain Penicillium cyclopium westling (CMI 89374) was maintained 
on 2% malt-agar slants at 25 °C.
Cul tu re  conditions: (Raulin-Thom solution)
Glucose 50 g
Tartaric acid 2.66 g
Ammonium tartrate 2.66 g
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Ammonium hydrogen phosphate 
Ammonium sulphate 
Potassium carbonate
0.4 g 
0.17 g 
0.4 g 
0.27 g 
0.05 g
Magnesium carbonate 
Ferrous sulphate
(FeS04  * 7H20) 
Zinc sulphate
(ZnS04  * 7H20)
0.05 g
Deionised water 1000 ml
General procedure: 200 ml of culture medium was put into 1L Roux bottle flasks 
which were plugged with cotton wool and sterilised (Ref. 59). Each flask was incubated 
with a 2 ml portion of a spore suspension, in sterile deionised water, of Penicillium  
cyclopium westling strain (CMI 89374) which had been cultivated on 12 malt-agar slopes 
at 24 °C for 10 days. The mould was allowed to grow on the surface. After 4 days, the 
surface of the medium in most of the flasks was practically covered with a thin, white 
growth showing occasional green patches of sporing growth. After 6 days the medium in 
almost all flasks was covered with a somewhat fragile bright parrot-green felt which had 
an orange or pinkish-orange reverse. The culture solution was now bright orange in 
colour. Precursors were dissolved in sterile deionised water and fed to 6 days old cultures 
of Penicillium cyclopium , and the concentration of the precursor was 5 mM. The top 
layer of the mycelium was kept to the minium disturbance in case of low incorporation. 
The fed flasks were incubated at 25 °C for 10 days more, and then the mycelium was 
washed with water and discarded and the culture media and washings were combined. 
The combined aqueous solution was extracted with distilled ethyl acetate at the end pH. 
Evaporation of ethyl acetate extracts gave the products as oils which failed to be 
recrystallised.
1 4 6
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Feeding o f o-F  phenylalanine (38).- o-F Phenylalanine (223 mg) in sterile 
deionised water (18 ml) was fed in two batches to a 6 days old culture of Penicillium  
cyclopium as described in the general procedure. In the first batch the phenylalanine was 
fed in two portions to the culture medium, i.e. the concentration of the substrate was 2.5 
mM each feeding. An oily product was obtained which was identified by its mass 
spectrum (see Table 3 & 4).
Feeding of m-F phenylalanine (39). - m -F Phenylalanine (223 mg) in sterile 
deionised water (18 ml) was fed to a 7 days old culture of Penicillium cyclopium . The 
product was identified by its mass spectrum (see Table 3 & 4).
Feeding of p-F  phenylalanine (40). - p -F Phenylalanine (223 mg) was fed to a 6 
days old culture of Penicillium cyclopium , and the product was identfied by its mass 
spectrum (see Table 3 & 4).
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